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ABSTRACT 
Many skeletal diseases, such as osteoporosis and malignant bone metastases, are 
generally osteolytic and associated with increased bone resorption and decreased bone 
strength. Within a complex cytokine environment, the proteins RANKL and M-CSF are 
critical for osteoclast differentiation and activation, and thus fundamental effectors of 
osteolytic disorders. Previous studies showed that M-CSF stimulates the proliferation and 
early differentiation of osteoclast progenitors to osteoclast lineage, while RANKL targets 
the later stages of fusion and activation, and stimulates the formation of functional active 
osteoclasts. However, impacts of artificially elevated levels of these proteins on the 
skeleton system have not been fully characterized.   
In this project, we amplified the circulating levels of RANKL and M-CSF by 
injections or continuous administrations and examined the effects on bone volume and 
quality. We hypothesized that while M-CSF and RANKL can both stimulate 
osteoclastogenesis, the differences in activation stages targeted by these two cytokines 
would result in distinct responses on bone biomechanics. RANKL would directly 
stimulate osteoclast activity and increase bone resorption, while M-CSF would act 
anabolically through coupling between osteoblast development and the promoted 
osteoclastogenesis at the early stage, and promote bone formation indirectly. 
Data obtained in this project demonstrated that in vivo administration of RANKL 
and M-CSF induced general opposing effects on bone volume, architecture, 
mineralization and strength. RANKL directly stimulated bone resorption and reduceed 
bone biomechanical properties. The destructive skeleton induced by RANKL could serve 
 iii
as a novel animal model that exhibits a series of skeletal complications similar to those 
observed in osteolytic skeletal diseases, such as osteoporosis. Alternately, administrations 
of M-CSF markedly stimulated trabecular bone formation and had less of an influence on 
cortical bone. These changes demonstrated the potential of M-CSF as an anabolic agent 
for osteoporosis. 
This project has further examined the in vivo characteristics and functional effects 
of RANKL and M-CSF on the skeleton system. Findings in this project, such as the 
creation of RANKL induced bone loss model and characterization of the anabolic 
potential of M-CSF on the skeleton, could provide useful information and tools for 
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CHAPTER 1  
INTRODUCTION 
1.1 General Bone Biology 
1.1.1 Component and Function 
Bone is a specialized connective tissue composed of cells and extracellular 
matrix. Bone matrix is formed by collagen fibers (type I, 90% of the total protein), 
noncollagenous proteins, and inorganic minerals. Collagen fibers are oriented in specific 
directions and contribute to the flexibility and the great tensile strength of bone (Viguet-
Carrin, Garnero et al. 2006). Mineral crystals (primarily hydroxyapatite, accounting for 
65% of bone mass) surround and attach to the collagen fibers using the noncollagenous 
proteins, allowing bone to resist compression with its exceptional hardness (Buckwalter 
and Cooper 1987).  
Two primary types of bones make up the skeletal system (Figure 1.1). Cortical 
bone is the hard, outer shell that comprises 80% of the skeletal system (by mass). It 
exhibits advanced mineralization and has a slow turnover rate. Mature cortical bone 
consists of small units called osteons, which are organized in concentric layers of bone 
that surround a vascular channel. The other type of bone is trabecular bone (also known 
as cancellous or spongy bone). Trabecular bone is a network of small, connected struts 
that is weaker than cortical bone and located at the epiphyses of long bones and 
throughout the interior of short bones. Cancellous bone has a much higher turnover rate 
than cortical bone; therefore it is typically less mineralized (Heaney 2003).  
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Figure 1.1 Diagram showing basic bone structure (http://www.abdn.ac.uk/orthopaedics) 
Bone, together with cartilage, makes up the skeletal system and provides several 
essential functions to life. First, bones connect to each other by ligaments and provide 
both the framework of the body and mechanical support for movement (Kell, Bell et al. 
2001). Skeletal muscles attach to bones via tendons, and use bones as levers to move the 
body. Second, bones provide protection for the vital organs. For instance, the central 
nervous system is protected by the skull, and ribs protect the cardiovascular organs. The 
third function of bone is to serve as a reservoir for vital minerals (primarily calcium and 
phosphate). Calcium is an essential element that maintains and regulates a number of 
physiological activities; approximately 99% of the body’s calcium is stored in the 
skeleton in the form of hydroxyapatite and can be released into the blood stream for 
distribution to body parts when needed (Specker 1996). Finally, the marrow cavities in 
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certain bones (i.e. long bones) provide the microenvironment for blood cell formation 
(hematopoiesis).  
1.1.2 Bone Remodeling 
Bone is a dynamic tissue. In a mature skeleton, bone is continuously being broken 
down (bone resorption) and reformed (bone formation), allowing for the maintenance of 
bone tissue. This coordinated process is called bone remodeling. Bone remodeling is 
directed by the actions of the two major bone cells: osteoclasts (cells responsible for bone 
resorption) and osteoblasts (cells responsible for bone formation) (Parfitt 1984). The 
sequence of bone remodeling is always with resorption occurring first via active 
osteoclasts, followed by formation to form new bone tissue and resolve the defect 
(Ljunggren, Ljunghall et al. 1995).  
1.1.2.1 Bone Resorption by Osteoclasts 
Osteoclasts are giant multinucleated cells that differentiate from hematopoietic 
precursors of the monocyte/macrophage lineage (Udagawa, Takahashi et al. 1990). They 
are typically located in contact with a calcified bone surface or within a lacuna 
(Howship’s lacunae), usually with one or two in each resorption site (Vaananen, 
Hentunen et al. 1988). A most important feature of osteoclasts is the ruffled borders 
formed by deep foldings of plasma membranes in the area facing bone matrix (Figure 
1.2): The ruffled border is centrally located and surrounded by a ring of actin that serves 
to attach the cell to the bone surface, thus sealing off the bone resorbing compartment 
(Vaananen, Zhao et al. 2000).  
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Figure 1.2 Scanning electron micrograph showing an active osteoclast (Bone Research Society, 
www. brsoc.org.uk) 
When bone matrix is undergoing bone resorption by osteoclasts, lysosomal 
enzymes (Tartrate Resistant Acid Phosphatase, cathepsin K, etc.) are secreted into the 
extracellular bone resorbing compartment through the ruffled border (Zaidi, Pazianas et 
al. 1993). Since this compartment is sealed from the surrounding marrow cavity, enzymes 
are able to reach a high concentration. Accompanied with the lysosomal enzymes, 
protons are secreted by osteoclasts using proton pumps and across the ruffled border, thus 
causing an increase in the acidity of the extracellular compartment (Vaananen, Zhao et al. 
2000). Therefore, the extracellular bone resorbing compartment is functionally equivalent 
to a lysosome with low pH, high concentration lysosomal enzymes, and the substrate 
(bone matrix, figure 1.3). Resorption starts with the hydroxyapatite crystals being 
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mobilized by digestion of their links (the non-collagenous proteins) with collagen and 
dissolved by the acid environment. Then, the residual collagen fibers are digested either 
by the activation of collagenase or by the action of cathepsins at low pH. Residues from 
this extracellular digestion are internalized, transported through the cell and released at 
the basolateral domain, or released during the periods of relapse of the sealing zone 
(Lerner 2000).  
 
Figure 1.3 Picture illustrating osteoclastic bone resorption. The differentiated osteoclast polarizes 
on the bone surface, which involves matrix-derived signals transmitted by the αvβ3 integrin. 
After formation of the ruffled membrane, the osteoclast acidifies an extracellular 
microenvironment by means of an electrogenic proton pump. Intracellular pH is maintained by 
HCO3-/Cl- exchange at the cell’s antiresorptive surface. Cl-  ions pass through a ruffled membrane-
residing anion channel into the resorptive microenvironment, which achieves a pH approximating 
4.5. The acidic milieu mobilizes the mineral phase of bone and provides an optimal environment 
for organic matrix degradation by cathepsin K (Teitelbaum 2000). 
1.1.2.2 Bone Formation by Osteoblasts 
Osteoblasts are bone lining cells that are responsible for the production of bone 
matrix (collagens and ground substance). Osteoblasts originate from bone marrow 
stromal stem cells and connective tissue mesenchymal stem cells; under the regulation of 
a series of growth factors and cytokines, osteoblast progenitors proliferate and 
differentiate into preosteoblasts and then mature osteoblasts (Lian and Stein 1995). On 
bone surfaces, osteoblasts connect to each other via adhering junctions and enable 
intercellular communications; they function in clusters of around 100-400 cells along 
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each bone forming site (Stains and Civitelli 2005). When they receive signals from bone 
matrix, osteoblasts lay down osteoid (new bone matrix before it is mineralized) into bone 
resorption sites. In humans, the osteoid exists for approximately 10 days before 
mineralization is initiated, and the mineralized bone matrix is formed (Anderson 1989). 
Osteocytes are osteoblasts and bone-lining cells that were trapped within the matrix 
during the mineralization of bone. They are in direct communication with each other and 
with surface osteoblasts through their cellular processes. These intercellular 
communications have been indicated to play an important role in both the mineralization 
of bone and the detection and response to mechanical forces within bone matrix (Rodan 
1992).  
1.1.2.3 Bone Remodeling Process 
The process of bone remodeling can be divided into five stages (Parfitt 1984): 
quiescence, activation, resorption, reversal, formation and then back to quiescence 
(Figure 1.4). Quiescence refers to the resting state of bone surface. In this stage, the bone 
surface is surrounded by elongated osteoblasts called bone lining cells (LC, Figure 1.4). 
When bone remodeling is initiated, bone lining cells retract from the activated bone 
surface and the exposed mineralized surface attracts circulating preosteoclasts (POC, 
Figure 1.4) to aggregate, then fuse into multinucleated osteoclasts (activation phase). 
Afterwards, osteoclasts (OC, Figure 1.4) become activated and start to resorb the 
mineralized bone matrix during the resorption stage. In the reversal phase, cellular 
activities on the resorbed bone surface switch from resorption by osteoclasts to 
recruitment of osteoblasts. Osteoblasts aggregate on the bone resorption sites and then 















Figure 1.4 Bone remodeling phases. LC refers to bone lining cells (elongated osteoblasts), POC 
refers to preosteoclasts, OC refers to osteoclasts, and OB refers to osteoblasts. 
Bone remodeling is the result of interactions among multiple elements, including 
osteoblasts, osteoclasts, hormones, growth factors, and cytokines (Mundy 1993). In a 
healthy skeleton, activities of bone resorption and formation are coupled, meaning that 
bone formation always occurs following the previous bone resorption, as the bone 
remodeling process describes. The phenomena is largely related to the signals initiated 
during bone matrix resorption and then transferred to osteoblasts and pre-osteoblasts via 
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local regulatory network (Howard, Bottemiller et al. 1981; Locklin, Khosla et al. 2003). 
Accordingly, a series of factors which can promote or inhibit osteoclastic bone resorption 
result in similar stimulation or inhibition of osteoblast activation and bone formation 
(Manolagas and Jilka 1995). Under normal conditions bone remodeling is a balanced 
process that allows a renewal of 5-10% of bone volume each year (Fernandez-
Tresguerres-Hernandez-Gil, Alobera-Gracia et al. 2006). However, this balanced network 
can be disrupted in some pathological conditions, leading to the onset of skeletal 
diseases, including osteoporosis, osteopetrosis, Paget’s disease, and bone malignant 
metastasis (Manolagas and Jilka 1995; Blair, Zhou et al. 2006).  
1.1.3 Bone Biomechanics 
As described at the beginning of this chapter, bone serves four major functions, 
the first two relate to bone’s biomechanical role in the body. First, bones serve as levers 
against muscle contractions and support body movement; second, bones shield vital 
organs from trauma. Bone fragility, or bone strength, is used to indicate the  
biomechanical status of bone, representing bone’s susceptibility to fracture (Turner 
2002). Bone strength has many determinants, including the intrinsic properties of bone 
tissue (bone material properties), bone mass (also referred as bone volume in preclinical 
studies), and bone structural properties, such as bone size, cortical thickness, porosity, 
and architecture (Turner 2002; Ammann and Rizzoli 2003; Burr 2004). Clinically, bone 
strength is generally estimated by bone mineral density (BMD) using dual-energy X-ray 
absorptiometry (DXA). DXA measures the amount of minerals (calcium) present in bone 
and compares with normal data from specific age and race to predict fracture risk; it is the 
most commonly used tool to clinically diagnose osteoporosis. However, as BMD itself 
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only accounts for 60-70% of bone strength, many important factors cannot be captured by 
DXA (Friedman 2006; Turner 2006). For instance, the fracture risk in a 75-year-old 
woman is 4-7 times as that in a 45-year-old woman with identical BMD (Hui, Slemenda 
et al. 1988). These important bone strength determinants, other than BMD, can be 
broadly defined as bone quality (Burr 2004). Bone quality is mainly comprised of the 
material properties of bone tissue and bone structural properties, and is also largely 
influenced by bone turnover rates. 
1.1.3.1 Material Properties of Bone 
Bone tissue is a composite material composed mostly of type I collagen and 
minerals. Type I collagen has little influence on the stiffness of bone, particularly in 
compression, but has a profound effect on its toughness (Burr 2002; Wang, Shen et al. 
2002). Regulated by the nature of applied stress on bone, collagen fibers grow in 
preferential orientations (Martin and Ishida 1989) and contribute to the tensile strength of 
bone (Riggs, Vaughan et al. 1993; Takano, Turner et al. 1999). Collagen fibers can also 
enhance bone’s toughness by increasing the amount of cross-linking (Zioupos, Currey et 
al. 1999). Studies have shown that the decreased extent of collagen fiber crosslinking 
with aging reduces bone’s energy to failure, leading to increased fracture risk (Zioupos, 
Currey et al. 1999). On the other hand, minerals contribute largely to bone’s stiffness and 
resistance to compressive force due to its hardness. Most bone minerals exist in the form 
of hydroxyapatite crystals: Ca10(PO4)6(OH)2. These calcium phosphate crystals have 
spindle- or plate-like shapes and connect to collagen fibers via the non-collagenous 
proteins (anionic complexes with high ion-binding capacities).  
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In healthy bones, minerals and collagen fibers maintain a ratio that lead to 
biomechanical properties sufficient to withstand normal loading of bone, but this ratio 
varies in other conditions, leading to increased fracture risk (Currey, Brear et al. 1996). 
For instance, bones from osteopetrotic patients (bone minerals over-accumulate, 
hypermineralization) are very stiff, but also very brittle and result in reduced energy to 
failure. In contrast, patients with osteomalacia have high turnover, less mineralized bone 
(hypomineralization), which are ductile and can undergo large deformation without 
breaking but are poorly mineralized and weak. Both hypo- and hypermineralization 
reduce bone mechanical properties (Currey 1975; Currey, Brear et al. 1996). 
1.1.3.2 Structural Properties of Bone 
The structural properties of bone depend on mass distribution throughout the 
structure. From the macroscopic perspective, bone size is an important component. With 
the same cross-sectional area, bones with a larger diameter are stronger in resisting 
bending stress than smaller bones with thicker cortical walls. Distribution of bone 
materials further from the neutral axis of bone contributes to a higher polar moment of 
inertia (pMOI, which is used to predict object’s ability to resist torsion, and also widely 
used in bone engineering to predict cortical geometry and the ability to resist bending 
load). 
Besides bone size, intrinsic bone geometry also determines bone structural 
properties and strength. Trabecular bone geometry is an important component of bone 
structural properties. Trabecular bones exist at the ends of long bones and throughout the 
inside of short bones. The small plate-like structures (individual trabeculae) of trabecular 
bone are connected to each other to appropriately distribute forces throughout the shaft. 
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In osteoporotic conditions, loss of trabecular connectivity decreases the capability of the 
trabecular meshwork to effectively distribute forces. Without a great change in bone 
mineral density, bone strength can be largely decreased due to the loss of connectivity 
between trabeculae struts. This can be demonstrated by antiresorptive therapies on 
osteoporosis patients: One-year treatment of bisphosphonates (a category of 
antiresorptive treatment) decreased fracture risk by 50-60% with only 5% increase in 
bone mineral density (Burr 2004).  
Besides trabecular geometry, cortical bone geometry also contributes to the 
structural properties of bone. Bone geometry change induced by anabolic treatments of 
osteoporosis is a common example. Parathyroid hormone (Teriparatide, PTH I-34) 
stimulates new bone formation at the periosteal (outside) surface and lowers fracture risk 
in osteoporotic patients. At the same time, PTH also induces an increase in cortical 
porosity and partly counteracts the positive effects on bone strength (Burr, Hirano et al. 
2001). It is the deposition of bone at the periosteal surface, having a greater contribution 
to torsional and bending moments of inertia, that more than compensates for this greater 
porosity 
1.1.3.3 Influence of Turnover on Bone Biomechanics  
Bone turnover, which represents the rate bone is remodeled, is an important 
determinant of bone quality (Heaney 2003). Normal bone turnover rates in healthy 
individuals ensure the balance between old bone removal and new bone formation. 
Variations in bone turnover interrupt bone remodeling balance and result in direct 
changes in bone material and structural properties, as seen in aged people or patients with 
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skeletal disease (Parfitt 2002). High or low bone turnover rate cause different changes in 
bone material and structural properties, but both compromise bone biomechanics.   
An abnormally high bone turnover results in increased bone resorption rates, 
decreased bone mass, decreased bone mineralization, and decreased bone strength 
(Heaney 2003). An extreme example with pathologically high bone turnover rates is 
Paget’s disease. Symptoms of Paget’s disease include the presence of large, woven, less 
mineralized bone and skeletal abnormity, bones are ductile and weak (Raisz 1999; Siris 
1999; Whyte 2006). As described above, PTH as an anabolic agent increases overall bone 
remodeling speed (turnover rate), resulting in increased cortical porosity (Turner 2002; 
Burr 2005). 
In contrast, an unusually low turnover rate leads to microdamage accumulation 
and hypermineralization of bone matrix, resulting in brittle bone and increased risk of 
fracture. Osteopetrosis is an extreme example of low bone turnover induced by defects in 
osteoclast formation and function. In the skeletons of osteopetrosis patients, defects in 
bone resorption induce accumulation of microdamage; bones are thick and dense but 
brittle and abnormal (Tolar, Teitelbaum et al. 2004). Decreased bone turnover is usually 
associated with antiresorptive therapy of osteoporosis (i.e. bisphosphonates). 
Bisphosphonates stimulate osteoclast apoptosis, inhibit osteoclastic bone resorption, and 
decrease bone turnover. However, bisphosphonates also compromise the removal of 
microdamaged bone and enable the accumulation of microfractures, thus degrade bone 
quality. Potential long-term negative effects induced by bisphosphonates have attracted 
much debate and concern recently; details will be discussed later in this chapter (Sibilia 
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and Netti 1996; Rodan, Reszka et al. 2004; Iwamoto, Takeda et al. 2006; Liberman 
2006). 
1.2 Osteoclastogenesis 
Osteoclasts are multinucleated giant cells responsible for bone resorption. They 
maintain bone homeostasis by resorbing the old, damaged bones and initiate bone 
remodeling. Among the various skeletal diseases known to occur in humans, the majority 
of them are triggered by abnormalities in osteoclast development or function. These 
osteoclast abnormalities can be divided into two distinct situations. First, the loss of 
function in osteoclasts, due to problems in differentiation or abnormal apoptosis, leads to 
osteopetrosis with little or no osteoclasts activity and a dense but brittle skeleton (Marks 
1987; Tolar, Teitelbaum et al. 2004). On the other hand, excessive number and activity of 
osteoclasts initiate osteolytic bone diseases, including osteoporosis, rheumatoid arthritis 
and malignant bone metastases, resulting in bone loss, deterioration in architecture, and 
decrease bone biomechanical properties (Teitelbaum 1996; Boyce, Xing et al. 2003). 
Osteolytic bone diseases are most common (Rodan and Martin 2000), and are induced by 
excessive level of osteoclastogenesis due to abnormalities in regulation signals that are 
released into the bone microenvironment. Osteoclastogenesis regulation is a complicated 
process, with many cells, hormones, and cytokines involved; exact mechanisms in 
various situations are still unclear. Therefore, to better understand the skeletal diseases, it 
is important to understand the osteoclastogenesis pathway and its regulation system. 
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1.2.1 Origin of Osteoclasts 
In the 1980s, significant debate and confusion existed on the origin of osteoclasts. 
The classic concept was that osteoclasts originated from connective tissue cells, while 
others hypothesized that it originated from mature hematopoietic cells, particularly from 
monocyte or macrophage cells (Hanaoka, Yabe et al. 1989). In 1990, researchers using an 
in vitro cell coculture system demonstrated that macrophages could differentiate into 
osteoclasts with the presence of bone marrow stromal cells and their osteoblast 
progenitors (Udagawa, Takahashi et al. 1990). This proved for the first time the concept 
that osteoclasts are derived from haematopoietic stem cells of the monocyte/macrophage 
lineage in the bone marrow.  
Hematopoietic stem cell precursors first undergo a phase of determination to 
acquire the potential of becoming either osteoclasts or macrophages. After proliferation, 
committed precursors differentiate to become either cell type. Studies have shown that 
the transcription factor PU.1 is critical for the initial commitment or determination phase: 
Its deletion results in osteopetrosis without either osteoclasts or macrophages (Tondravi, 
McKercher et al. 1997). 
1.2.2 Regulation of Osteoclastogenesis  
Under a series of regulations, hematopoietic stem cells experience several 
processes, including proliferation, differentiation, fusion, and activation, and become 
functional active osteoclasts (Figure 1.5). The active osteoclasts eventually have the 
capability to resorb bone. Breakthroughs have occurred in this field during the past 
decade and have increased people’s understanding in osteoclast biology. It is now clear 
that cells required for in vitro osteoclast culture, osteoblasts and stromal cells, express 
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two essential molecules that are necessary and sufficient to promote osteoclastogenesis: 
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear kappa B 
(RANK) ligand (RANKL) (Teitelbaum 2000). In vitro osteoclast development could be 
achieved by pure macrophages exposed to M-CSF and RANKL (Lacey, Timms et al. 
1998), indicating the indispensable role of osteoblasts/stromal cells in osteoclastogenesis 
through the release of these two cytokines. Different numbers and activities of osteoclasts 
can be modulated by varying the concentrations and ratio of these two proteins in the 
















Figure 1.5 Osteoclastogenesis regulation. The transcription factor PU.1 is critical for the initial 
commitment or determination phase. M-CSF is necessary for proliferation and differentiation, as 
well as the survival of osteoclast progenitors. RANKL is the key regulator for the latter stages, 
primarily the fusion of preosteoclasts and the final activation phase.   
M-CSF is a cytokine expressed by osteoblasts and stromal cells. It binds to its 
receptor c-fms on early osteoclast precursors, thus stimulating early stage 
osteoclastogenesis, particularly proliferation and differentiation (Kodama, Nose et al. 
1991; Corboz, Cecchini et al. 1992; Felix, Halasy-Nagy et al. 1996). The important role 
of M-CSF in osteoclastogenesis has been confirmed in vivo using M-CSF-deficient 
osteopetrotic (op/op) mice: Mice with a specific knock-out of the M-CSF gene developed 
profound osteopetrotic phenotype with little or no osteoclast activity (Wiktor-
Jedrzejczak, Bartocci et al. 1990; Yoshida, Hayashi et al. 1990). Subsequent studies 
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showed that systemic administration of recombinant human M-CSF to op/op mice 
increased the number of osteoclasts and led to partial or complete resolution of the 
osteopetrotic defect (Kodama, Yamasaki et al. 1991; Sundquist, Jackson et al. 1995; 
Abboud, Woodruff et al. 2002). However, no evidence was found that indicate M-CSF 
plays a role in the activation phase of osteoclastogenesis. In contrast, a few studies 
indicated that high concentration of M-CSF could potentially inhibit osteoclast activity 
by inhibiting osteoclast activation (Perkins and Kling 1995; Abboud, Ghosh-Choudhury 
et al. 2003). Detailed mechanisms of M-CSF will be discussed later in this chapter.  
RANKL was discovered in 1998 and has been proven to be an important mediator 
for osteoclastogenesis, which stimulates the latter stages of osteoclastogenesis: fusion, 
survival, and activation (Figure 1.5). RANKL binds to its receptor RANK on the surface 
of osteoclasts and their precursors, stimulates the activation of pre-osteoclasts to 
functionally mature osteoclasts, and induces bone resorption (Lacey, Timms et al. 1998; 
Yasuda, Shima et al. 1998). Osteoprotegerin (OPG) is the decoy receptor for RANKL. It 
competes with RANK for the binding of RANKL, therefore decreasing RANKL-RANK 
interaction and inhibiting bone resorption (Simonet, Lacey et al. 1997; Tsuda, Goto et al. 
1997). Transgenic mice over-expressing RANKL, and OPG-knockout mice (OPG-/-) 
developed severe osteoporosis symptoms including increased osteoclast numbers and 
activities, low bone-mineral density, and high bone turnover (Kostenuik and Shalhoub 
2001; Mizuno, Kanno et al. 2002). Detailed mechanisms of RANKL/OPG and their roles 
in osteoclastogenesis will be discussed in the next section. 
M-CSF and RANKL do not function alone to regulate osteoclastogenesis. Certain 
hormones and cytokines produced in distant organs can also influence osteoclastogenesis 
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(Figure 1.6). It has been shown that pro-resorptive factors, including tumor necrosis 
factor α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), 1,25(OH)2 vitamin D3, 
prostaglandin E2 (PGE2), parathyroid hormone (PTH), and PTH-related peptide 
(PHTrP), can upregulate RANKL expression by osteoblasts, consequently stimulating 
osteoclastogenesis and inducing bone resorption (Udagawa, Takahashi et al. 2000; 
Schoppet, Preissner et al. 2002). On the other hand, antiresorptive factors can inhibit 
osteoclastogenesis by decreasing RANKL expression or increasing OPG release. This 
category of factors includes calcitonin, oetrogens, transforming growth factor β (TGF-β), 
TPO, IL-17, interferon γ (INF-γ), and Platelet-derived growth factor (PDGF) 
(Nakashima, Kobayashi et al. 2000; Boyle, Simonet et al. 2003). 
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Figure 1.6 Hormonal regulations systems on osteoclastogenesis (Boyle, Simonet et al. 2003). 
PTH: Parathyroid hormone; PTHrP: PTH related peptide; PGE2: Prostaglandin E2; IL: 
Interleukin; TNF: Tumor necrosis factor; LIF: Leukemia inhibitory factor; BMP: Bone 
morphogenetic protein; TGF-β: Transforming growth factor β; TPO: Thrombopoietin; PDGF: 
Platelet-derived growth factor. 
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1.3 RANK/RANKL/OPG System 
Over the past two decades, the largest breakthroughs in bone biology have been 
triggered by the identification and characterization of the RANK/RANKL/OPG system 
(Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997; Lacey, Timms et al. 1998; Yasuda, 
Shima et al. 1998).  
As first noted in 1990, preosteoblasts and stromal cells regulate osteoclast 
differentiation both by producing soluble factors and signaling to osteoclast progenitors 
through cell-cell interaction (Udagawa, Takahashi et al. 1990; Suda, Takahashi et al. 
1992). However, the critical factor produced by these cells mediating osteoclastogenesis 
remained unknown for the next several years; bone biologists performed searches trying 
to identify this mediator, and finally in 1997 and 1998, the identification of 
RANK/RANKL/OPG system as the critical and final mediator of osteoclastogenesis 
ended this obscurity (Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997; Lacey, Timms 
et al. 1998; Yasuda, Shima et al. 1998). Osteoprotegerin (OPG) was first identified as a 
TNF superfamily soluble member that inhibits osteoclastogenesis (Simonet, Lacey et al. 
1997). Overexpression of OPG in the livers of transgenic mice resulted in osteopetrosis 
(Simonet, Lacey et al. 1997); in contrast, disruption of the OPG gene (OPG-/- mice) 
produced a high bone turnover osteoporotic phenotype (Bucay, Sarosi et al. 1998). 
Subsequently, RANKL was identified to be the molecule, present in both membrane-
bound and soluble forms, that was blocked by OPG and functions as the key mediator of 
osteoclastogenesis (Lacey, Timms et al. 1998; Yasuda, Shima et al. 1998). These seminal 
papers have initiated numerous studies on the RANK/RANKL/OPG system.  
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1.3.1 Osteoprotegerin 
OPG is a glycoprotein secreted by osteoblasts and stromal cells in the bone 
microenvironment and binds to RANKL as a decoy receptor inhibiting 
osteoclastogenesis. OPG was discovered in 1997 by two groups in two different ways 
(Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997). In a project focused on identifying 
TNF receptor-related molecules that potentially have therapeutic utility, the Amgen Inc. 
group found a particular cDNA in the rat intestine. Overexpression of this gene in a 
mouse resulted in an osteopetrotic phenotype accompanied by a profound decrease in 
osteoclasts (Simonet, Lacey et al. 1997). Later studies found that transgenic mice with 
OPG gene knockout showed less bone mineral density and other severe osteoporosis 
symptoms (Mizuno, Amizuka et al. 1998) (Figure 1.7). This study first discovered OPG 
and indicated that it plays an important role in osteoclastogenesis. A month later, the 
Snow Brand Milk Group in Japan reported a novel cytokine from the conditioned 
medium of human embryonic lung fibroblasts cultures that inhibited osteoclastogenesis 
(Tsuda, Goto et al. 1997). This factor, termed osteoclastogenesis inhibitory factor 
(OCIF), later proved to be identical to OPG (Yasuda, Shima et al. 1998). 
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Figure 1.7 Transgenic mice with OPG knockout showed severe osteoporosis symptoms (Mizuno, 
Amizuka et al. 1998). 
In contrast to other TNF receptor superfamily members, OPG lacks 
transmembrane and cytoplasmic domains and is therefore secreted as a soluble protein 
with 380 amino acids. OPG mRNA is expressed in many tissues, including bone, lung, 
heart, kidney, liver, stomach, intestine, brain spinal cord, and thyroid gland (Simonet, 
Lacey et al. 1997; Yasuda, Shima et al. 1998). In addition to severe osteoporosis, mice 
with the OPG gene knock-out also developed calcification in large aortas (Bucay, Sarosi 
et al. 1998; Mizuno, Amizuka et al. 1998); studies have shown that OPG may be 
important for the survival of endothelial cells (Malyankar, Scatena et al. 2000). These 
findings indicate that the RANK/RANKL/OPG system might be involved in the 
regulation mechanism of the cardiovascular system. For this reason, vascular calcification 
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induced by RANKL was examined in an in vivo study of this project (see Chapter 4 for 
details).  
1.3.2 RANKL and RANK 
RANKL was identified by both Amgen and the Snow Brand Milk Group using 
expression cloning with OPG as a probe, this time with the Japanese group reporting their 
results first (Lacey, Timms et al. 1998; Yasuda, Shima et al. 1998). This protein was 
initially termed OPG ligand (OPGL) and osteoclast differentiation factor (ODF), which 
later turned out to be identical with two previous known members of the TNF ligand 
family: TNF-related activation induced cytokine (TRANCE) and RANKL, a factor 
known to stimulate dendritic cells (Anderson, Maraskovsky et al. 1997; Wong, Rho et al. 
1997). This protein was eventually termed RANKL. 
RANKL is a 317-amino acid family peptide that belongs to the TNF superfamily 
of cytokines. RANKL exists in two forms: a 40- to 45-kDa membrane-bound form and a 
31kDa soluble form derived by cleavage of the full-length form at position 140 or 145 
(Lacey, Timms et al. 1998). RANKL mRNA is expressed in various tissues, with highest 
levels in bone and bone marrow, as well as in lymphoid tissues (Anderson, Maraskovsky 
et al. 1997; Wong, Rho et al. 1997; Lacey, Timms et al. 1998; Yasuda, Shima et al. 
1998). Although RANKL was originally identified as a dendritic cell survival factor 
produced by activated T cells, subsequent studies have established the role of RANKL 
being the primary mediator and final effector of osteoclastogenesis. Its role and 
importance to the immune system is still being identified, while its critical role in 




Figure 1.8 Mechanism of action of RANKL (Amgen Inc., Thousand oaks, CA). OB: Osteoblast; 
CFU-M: Colony forming unit- macrophage. 
   
RANK, the receptor of RANKL, belongs to the TNF receptor superfamily  
(Anderson, Maraskovsky et al. 1997). RANK mRNA is highly expressed in osteoclast 
progenitors and mature osteoclasts (Hsu, Lacey et al. 1999). RANK knock-out transgenic 
mice showed profound osteopetrosis due to the lack of osteoclasts (Li, Sarosi et al. 2000), 
demonstrating RANK as the sole receptor for RANKL during osteoclastogenesis. 
RANKL interacts with the RANK receptor to recruit TNF receptor–associated factor 6 
(TRAF-6), a member of TNF family signal transducers (Theill, Boyle et al. 2002). 
TRAF-6 binds to one or more of four binding sites in the intracellular domain of the 
RANK receptor and then signals downstream through several signaling cascades, most 
notably those involving NF-κB, mitogen-activated protein (MAP) kinases (extracellular 
 24
signal-regulated kinase [Erk], Janus N-terminal kinase [JNK], and p38), and Akt-2 
(Theill, Boyle et al. 2002). 
1.3.3 RANK/RANKL/OPG System in Skeletal Diseases 
The RANKL to OPG ratio has been suggested to represent a potentially important 
determinant of bone remodeling, and an increased RANKL:OPG ratio is evident in 
various bone diseases (Blair, Zhou et al. 2006). These disorders range from traditional 
causes for osteoporosis to localized inflammatory conditions leading to osteolysis and 
include cancer, particularly when metastasized to bone.   
Estrogen deprivation in postmenopausal women stimulates the production of a 
variety of regulatory cytokines, such as IL-1β, IL-6, TNF-α, and M-CSF, which promote 
RANKL production and stimulate osteoclast formation and activation (Suda, Takahashi 
et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003). In a study targeting postmenopausal 
osteoporosis patients, RANKL concentration was shown to correlate with the bone 
resorption markers, serum C-terminal telopeptide and urine N-telopeptide of type I 
collagen, indicating RANKL as the final effector of osteoclastogenesis (Eghbali-
Fatourechi, Khosla et al. 2003).  
In an inflammatory environment, such as in rheumatoid arthritis, cytokines 
released by the immune cells (IL-1, TNF-α, IL-6) increase the RANKL:OPG ratio and 
lead to joint destruction and bone loss (Kong, Feige et al. 1999; Lubberts, van den 
Bersselaar et al. 2003; Stolina, Adamu et al. 2005). Additionally, RANKL also plays an 
important role in malignant diseases, such as multiple myeloma and osteolytic bone 
metastases. Myeloma cells enhance RANKL release and down-regulate OPG expression, 
thereby increasing bone resorption while inhibiting bone formation, which uncouples 
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bone remodeling and leads to accelerated bone loss (Giuliani, Bataille et al. 2001; 
Standal, Seidel et al. 2002). In osteolytic bone metastases, such as breast and lung cancer, 
tumor cells directly express RANKL and/or indirectly increase RANKL levels through 
expression of PTH related peptide (PTHrP), resulting in bone lesions (Michigami, Ihara-
Watanabe et al. 2001; Mundy 2002).  
1.4 Macrophage Colony Stimulating Factor 
As a known key regulator for the proliferation and differentiation stages of 
osteoclastogenesis, M-CSF (also known as colony stimulating factor-I [CSF-I]) was 
originally defined by its ability to stimulate the preferential growth of macrophage 
colonies from bone marrow precursors (Stanley, Guilbert et al. 1983). Subsequent studies 
found that M-CSF is a haematopoietic growth factor that stimulates the survival, 
proliferation, differentiation and functions of cells from the mononuclear phagocytic 
lineage (Rettenmier and Sherr 1989) (Figure 1.9). M-CSF is primarily produced by 
connective tissue cells (including osteoblasts) and exists in both soluble and membrane-
bound forms. The membrane-bound form is expressed as an integral transmembrane 
glycoprotein, whereas the soluble form is rapidly secreted into the circulation as a 
glycoprotein or chondroitin sulfate-containing proteoglycan. Both isoforms act on the 
target cells through a specific cell surface tyrosine kinase receptor encoded by the c-fms 
proto-oncogene. M-CSF receptor (CSF-1R) contains an extracellular ligand-binding 
domain, a transmembrane domain, and an intracellular tyrosine domain. M-CSF is a 
disulfide-linked homodimer that, by binding to CSF-1R, stabilizes CSF-1R dimerization 
to activate the receptor through autophosphorylation, thereby initiating a series of 
membrane-proximal tyrosine phosphorylation cascades, leading to rapid stimulation of 
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cytoskeletal remodeling, gene transcription, and protein translation (Yeung and Stanley 
2003).  
 
Figure 1.9 M-CSF action in bone and other tissues. M-CSF (CSF-1) synergizes with 
hematopoietic growth factors (HGFs) to generate mononuclear progenitor cells from multipotent 
progenitors, and with RANKL to generate osteoclasts from mononuclear phagocytes. Red arrows 
indicate cell differentiation steps; blue arrows indicate cytokine regulation (Pixley and Stanley 
2004).  
1.4.1 The Central Role of M-CSF in Osteoclastogenesis 
Numerous in vitro and in vivo studies have been done to prove that M-CSF is a 
critical regulator of osteoclastogenesis. Takahashi et al. demonstrated that M-CSF is 
central for the proliferation of osteoclast progenitors derived from committed 
granulocyte-macrophage progenitors (CFU-GM) (Takahashi, Udagawa et al. 1991). 
Pretreatment of bone marrow cells with M-CSF in the culture media for 6 days before 
incubation with normal osteoblasts resulted in the formation of numerous osteoclast-like 
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multinucleated cells in the presence of vitamin D3. Subsequently, Tanaka et al. 
demonstrated that M-CSF was required for both the proliferation and differentiation of 
osteoclast progenitors (Tanaka, Takahashi et al. 1993). Spleen cells are a source of 
osteoclasts; when co-cultured with mouse osteoblasts and incubated with either anti-M-
CSF or c-fms antibody during the proliferation and differentiation phases, osteoclast 
formation that was induced by 1,25(OH)3D3 was inhibited. The ability of M-CSF to 
stimulate osteoclast development and function in vivo has been confirmed using the M-
CSF deficient osteopetrotic (op/op) mouse model (Wiktor-Jedrzejczak, Bartocci et al. 
1990; Yoshida, Hayashi et al. 1990). Systemic administration of recombinant human 
soluble M-CSF to op/op mice had been shown to increase the number of osteoclasts and 
led to partial or complete resolution of the osteopetrotic defect (Kodama, Yamasaki et al. 
1991; Wiktor-Jedrzejczak, Urbanowska et al. 1991; Sundquist, Cecchini et al. 1995).  
1.4.2 The Antiresorptive Potential of M-CSF 
The action of M-CSF on bone is complex. Though being a potent promoter of 
osteoclast proliferation and differentiation, M-CSF inhibits mature osteoclasts activity 
thus decreasing bone resorption. In a study using ST-2 stromal cell and murine bone 
marrow coculture, exogenous M-CSF caused a 98% dose-dependent decrease in tartrate-
resistant acid phosphatase (TRAP) positive multinucleated cells (Perkins and Kling 
1995). In studies using isolated mature rat osteoclasts, Hattersley et al. demonstrated that 
M-CSF, though enhanced osteoclast survival by preventing apoptosis, acted as a 
chemotactic agent and inhibited bone resorption (Hattersley, Dorey et al. 1988; Fuller, 
Owens et al. 1993). In vivo, transgenic mice selectively over-expressed soluble M-CSF in 
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bone and showed increased cortical thickness in the femoral diaphysis caused by new 
bone formation along the endocortical surface (Abboud, Ghosh-Choudhury et al. 2003). 
As a summary, these findings indicated that M-CSF is a key determinant for 
osteoclastogenesis both in vitro and in vivo. M-CSF exhibits bi-polar effects: it promotes 
osteoclast proliferation and differentiation while inhibiting osteoclast activation. 
However, the precise biological effects of M-CSF on bone formation, geometry, 
structure, and bone biomechanics remain unclear. Therefore, we performed in vivo 
studies with M-CSF to explore these unknown effects on bone biomechanics. Details will 
be presented in Chapter 5 of this project. 
1.5 Skeletal Diseases  
Under most conditions, osteoblast and osteoclast activities are closely coupled: a 
direct increase or decrease in the activity level of one cell type will lead to an indirect 
change in the other cell type in the same direction through cytokine signaling. There are, 
however, some skeletal pathologies characterized by uncoupled osteoclast and osteoblast 
activity, mostly exhibiting excessive osteoclast activity. This excessive osteolysis is an 
important clinical problem in many common lesions, including osteoporosis, cancer 
metastases in bone, inflammatory joint diseases, and implanted joint prosthesis failure. 
The following paragraphs will focus on osteoporosis and malignant bone metastases, 




Osteoporosis is currently defined as a systemic skeletal disorder characterized by 
low bone mass and bone microarchitecture deterioration (Figure 1.10), with a consequent 
increase in bone fragility and susceptibility to fracture (Consensus Development 
Conference, 1993). Clinically, osteoporosis is recognized by the occurrence of 
characteristic low trauma fractures, which typically arise at the hip, spine, and wrist. It is 
also a disease that increases in severity with age of the patient. The clinical diagnosis of 
osteoporosis is made if a bone densitometry scan demonstrates a bone mineral density 
(BMD) that is 2.5 standard deviations below the mean peak bone mass of young adult. 
Osteopenia (‘at risk’, low bone mass) is defined at BMD 1.0 standard deviations below 
normal (National Osteoporosis Foundation, www.nof.org).  
Osteoporosis is a major public health problem. According to the International 
Osteoporosis Foundation, osteoporosis affects an estimated 75 million people in Europe, 
USA and Japan.  Overall 30%-50% women and 15%-30% of men will suffer a fracture 
related to osteoporosis in their lifetime. Because hip fracture incidence rates increase 
exponentially with age, the number of hip fractures worldwide will rise from 1.3 million 
in 1990 to an estimated 2.3 million in 2020 (L Joseph Melton, et al. 2004). Treatments for 
osteoporosis related fractures are normally invasive surgeries, such as hip replacement. 
This substantial number of hip surgeries, in addition to the other fractures associated with 




Figure 1.10. Normal (left) and osteoporotic (right) human trabecular bone (Marx 2004). 
1.5.1.1 Mechanism of Osteoporosis 
Osteoporosis can be triggered by many factors, such as menopause, 
glucocorticoid therapies, and aging. Among these factors, estrogen deficiency in 
menopausal states is the most common cause. Estrogen is an important regulator of bone 
remodeling; it protects against bone loss. Studies have shown that estrogen deficiency is 
the cause of both the early and the late forms of osteoporosis in post-menopausal women 
and contributes to the development of osteoporosis in aging men (Khosla, Melton et al. 
2002; Riggs, Khosla et al. 2002). Estrogen deficiency is associated with an increase in 
bone resorption over bone formation, leading to excessive and sustained bone loss. The 
increase in bone resorption is due both to increased osteoclastogenesis and to decreased 
osteoclast apoptosis (Manolagas 2000). The mechanism of estrogen deficiency induced 
bone loss, though not fully understood, is largely related to the RANK/RANKL/OPG 
system by increasing RANKL/OPG ratio.  
Studies have shown that estrogen deprivation in postmenopausal women led to 
increased production of a variety of regulatory cytokines, such as IL-1β, IL-6, TNF-α and 
M-CSF, which boost RANKL production and thus osteoclast formation and activation 
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(Suda, Takahashi et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003). In a study using 
fluorescent-activated cell sorting to isolate osteoblast precursor cells from premenopausal 
women, women in early menopause without any treatment, and estrogen-treated 
postmenopausal women, researchers found that the cells from the untreated 
postmenopausal women carried much higher levels of RANKL than those from the 
women in the other two groups (Eghbali-Fatourechi, Khosla et al. 2003). In this study, 
the RANKL concentration also correlated with the bone resorption markers serum C-
terminal telopeptide and urine N-telopeptide of type I collagen, indicating RANKL as the 
final effector of osteoclastogenesis (Eghbali-Fatourechi, Khosla et al. 2003). By up-
regulating RANKL production, estrogen deficiency has several functional effects, 
including:  increased bone turnover rates, deep resorption cavities, trabecular plate 
perforation, wide separation and disconnection of trabeculae, and enlargement and 
coalescence of sub-endocortical spaces. 
Besides estrogen deficiency, incidence of osteoporosis increases with age. In 
aging skeletons, the number of osteoblasts that are recruited to erosion surfaces and 
osteoblast functional activity are decreased, resulting in a decreased rate of bone 
formation. Estrogen deficiency also suppresses survival of osteocytes and impairs the 
response of osteoblasts to mechanical stimuli and detection of microdamage, and 
therefore the repair of aged bone (Manolagas 2000). With increasing age in women as 
well as in men, microdamage accumulates more rapidly than intrinsic processes can 
repair, resulting in microarchitectural deterioration and decreased bone strength 
(Schaffler, Choi et al. 1995).  
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1.5.1.2 Osteoporosis Therapies 
Current therapies for osteoporosis can be classified to two major categories: 
antiresorptive and anabolic. Antiresorptive therapies target osteoclasts, either decreasing 
osteoclastogenesis or increasing osteoclast apoptosis. Over the past decades, most 
osteoporosis patients have been treated with antiresorptive agents such as estrogen and 
bisphosphonates. Researchers have long known that estrogen deficiency is the major 
cause of osteoporosis, however, the most obvious therapeutic strategy, hormone 
replacement therapy (HRT), had been implicated in increasing the risk of both breast 
cancer and cardiovascular diseases (Couzin 2003). Therefore antiresorptive therapies, 
namely bisphosphonates, have been used most extensively due to their safety and potent 
efficacies on inhibiting bone resorption. 
Bisphosphonates are a class of pyrophosphate analogues that bind with high 
affinity to the hydroxyapatite bone matrix, internalized by osteoclasts through 
endocytosis during bone resorption (Coxon, Thompson et al. 2006). This internalization 
leads to osteoclast apoptosis by inhibition of farnesyl diphosphate synthase, a key 
enzyme of the mevalonate pathway (Coxon, Thompson et al. 2006). Several 
bisphosphonates have been approved by FDA for treatment of osteoporosis, including as 
alendronate (ALN), risedronate (RIS), zoledronate (ZLN), and ibandronate (IBN) 
(Chapurlat and Delmas 2006). Clinical use of these drugs has been shown to improve 
patients’ bone mineral density, trabecular bone connectivity and decrease the risk of 
fracture. However, due to the coupling of bone resorption and bone formation, 
bisphosphonates can inhibit or reduce bone formation. After binding with bone matrix, 
bisphosphonate molecules can remain in the skeletal system for many years. 
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Accumulation of bisphosphonates due to long-term therapies can potentially over-
suppress bone turnover, impairing bone’s natural recovering ability and increasing 
fracture risk (Rodan, Reszka et al. 2004). 
Recombinant human parathyroid hormone (rhPTH, I-34) was approved by FDA 
in 2002 as an anabolic agent to treat osteoporosis through stimulating new bone growth. 
This anabolic bone-active agent stimulates osteoclasts to form new bone, primarily by 
stimulating new formation on quiescent bone surface that is not simultaneously 
undergoing remodeling. In a large clinical trial performed by Neer and colleagues, 
postmenopausal women patients receiving rhPTH increased BMD by 9-13% in the 
lumbar spine and 3% in the femoral neck (Neer, Arnaud et al. 2001). The anabolic effects 
of rhPTH have been demonstrated to be most pronounced in the trabecular bone, 
evidenced by increased trabecular number and connectivity (Dempster, Cosman et al. 
2001). Compared to the patients receiving placebo control, risk of new vertebral fractures 
was reduced by 65% and nonvertebral fractures reduced by 35% (Neer, Arnaud et al. 
2001). However, rhPTH is not an ideal treatment for osteoporosis. First, compare to the 
common weekly oral doses of bisphosphonates, it requires daily injection, which is 
inconvenient and limits compliance. Second, rhPTH injection also stimulates the 
production of osteoclast stimulating cytokines, primary RANKL and IL-6, thus 
increasing bone resorption simultaneously with bone formation and partly counteracts its 
positive effects on bone strength (Fu, Jilka et al. 2002). Furthermore, as an anabolic 
agent, rhPTH can potentially stimulate the growth of tumor cells and increase the risk of 
tumor incidence and metastasis. Therefore, to limit the risk of tumor initiation, current 
rhPTH therapy was approved for use for a maximum of two years. 
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In recent years, many studies have shown great potential in using 
RANK/RANKL/OPG system as a therapeutic target for osteoporosis. Strategies include: 
suppression of RANKL expression using 17 β-estradiol (Eghbali-Fatourechi, Khosla et 
al. 2003); RANKL blockage by soluble RANK fusion proteins, OPG fusion proteins, or 
RANKL antibodies (Min, Morony et al. 2000; Oyajobi, Anderson et al. 2001; Bekker, 
Holloway et al. 2004); and stimulation of OPG production (Onyia, Galvin et al. 2004). A 
clinical trial reported that a single dose of AMG 162, a RANKL antibody developed by 
Amgen (Thousand Oaks, CA), decreased bone resorption for up to 6 months when given 
to postmenopausal women.  The drugs effect in blocking bone resorption was at least 
comparable to bisphosphonates (Bekker, Holloway et al. 2004). 
1.5.2 Osteolytic Bone Metastasis 
Cancerous cells can remain in the particular organ of origin (primary cancer) or 
metastasize to other organs and tissues (metastatic cancer). Due to the highly 
vascularized structure and the cytokine and growth factor environment, the skeleton is the 
most common organ to be affected by metastatic cancer. Common tumors, such as breast, 
lung, and prostate frequently metastasize to bone. Bone metastases are often classified as 
either osteolytic or osteoblastic. The majority of malignant bone metastases are 
osteolytic, including breast and lung cancer, as well as those bone lesions found in 
multiple myeloma. These osteolytic bone metastases can result in severe bone pain, 
decreased bone mineral density, reduced bone strength, pathological fractures, and 
hypercalcemia (Mundy 2002; Blair, Zhou et al. 2006). On the other hand, prostate cancer 
bone metastases, as well as some other bone metastases, are osteoblastic. In these lesions, 
excess bone tissue is deposited in a disorganized woven structure, bones are weak and 
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pathological fractures frequently occur (Mundy 2002; Blair, Zhou et al. 2006). Due to the 
coupling between bone resorption and bone formation, there is no absolute osteolytic or 
osteoblastic cancers, most bone metastases show mixed patterns with the dominant lesion 
being osteolytic or osteoblastic, symptoms of the other lesion are usually evident. 
Osteolytic bone metastases induce abnormalities in bone remodeling primarily through 
stimulations on osteoclastogenesis. Studies have indicated that RANK/RANKL/OPG 
systems play an important role in this regulation process.  
1.5.2.1 Mechanisms of Osteolytic Metastases 
Among many regulation factors, PTH related peptide (PTHrP) is a key mediator 
of bone destruction in osteolytic cancers (Southby, Kissin et al. 1990; Powell, Southby et 
al. 1991; Miki, Yano et al. 2000; Bryden, Hoyland et al. 2002). It is well known that 
osteolytic breast cancer tumor cells can express PTHrP in vivo. Previous studies also 
show that PTHrP expression is greater when the tumor cells metastasize to bone than 
when they are present in soft tissue sites or in the breast (Southby, Kissin et al. 1990; 
Powell, Southby et al. 1991). In the bone microenvironment, the overproduction of 
PTHrP, as well as cytokines such as IL-1 and IL-6, stimulates osteoclast activity by 
stimulating RANKL production by osteoblasts and stromal cells. RANKL binds to 
RANK and triggers the intracellular signal transduction, leading to differentiation of 
osteoclast progenitors into mature osteoclasts (Figure 1.11). Moreover, PTHrP can 
decrease the production of OPG, thus further increasing the RANKL/OPG ratio. Some 
researchers also reported that RANKL can be released directly by the tumor cells that 
migrated to the bone microenvironment (Zhang, Dai et al. 2001). 
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Figure 1.11 The RANK/RANKL/OPG system in osteolytic bone metastases. Cytokines such as 
PTH or PTH-related peptide, interleukin (IL)-1, IL-6 and IL-11 stimulate production of RANKL 
by osteoblasts and stromal cells. Signaling through RANK in osteoclast progenitors activates 
transcription factors such as AP1 (activated by JUN N-terminal kinase (JNK), or JUN) and NF-
κB (activated by inhibitor of κB kinase (IKK)), leading to the differentiation of osteoclast 
progenitors into mature osteoclasts. These osteoclasts mediate bone resorption (Mundy 2002). 
Interaction between tumor cells and osteoclasts not only cause osteolytic bone 
destruction, but may also contribute to tumor proliferation. Active growth factors 
released during bone resorption, including primary insulin-like growth factor 1 (IGF-1) 
and TGF-β, together with the elevated extracellular calcium concentrations, can stimulate 
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the differentiation and growth of tumor cells (Yin, Selander et al. 1999; Yu and Rohan 
2000). The increased number and activity of tumor cells thus release more PTHrP into 
the bone microenvironment, inducing bone destruction through stimulating RANKL 
expression.  Increased RANKL will result in an increase in active growth factors levels 
via increased resorption, thus further stimulating tumor cell growth. Therefore, a vicious 
cycle exists in the mechanism pathway of osteolytic metastases (Figure 1.12). This cycle 
supports the growth of tumor cells metastasized to bone and their interrelations with bone 
remodeling, further contributing to the high frequency of the skeleton as a cancer 
metastatic site. 
 
Figure 1.12 The cycle of osteolytic metastases not only cause bone destruction, but also initiates 
a feedback loop that promotes tumor proliferation and therefore additional bone destruction 
(Mundy 2002). 
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1.5.2.2 Therapeutic Approaches 
Currently, bisphosphonates are widely used to treat osteolytic bone metastases 
through inhibiting bone resorption. These antiresorptive agents can interrupt the cycle by 
stimulating osteoclast apoptosis, thus decreasing the bone tumor burden and stimulating 
tumor cell apoptosis (Diel, Solomayer et al. 1998; Powles 1999). Recent studies show 
that the new generation of bone resorption inhibitors, such as OPG and RANKL antibody 
(AMG 162) which directly targets RANKL, might be more effective than 
bisphosphonates (Oyajobi, Anderson et al. 2001). Clinical studies have shown that OPG 
causes a rapid, sustained, dose-dependent decrease in bone resorption marker levels in 
multiple myeloma and breast cancer patients (Body, Greipp et al. 2003; Body, Facon et 
al. 2006). 
1.5.3 Animal Models for Skeletal Diseases 
Laboratory animals have played a major role in the enhanced understanding of 
skeletal diseases. Animals contributed to the knowledge of the etiology of osteoporosis 
and are essential for the preclinical evaluation of efficacy and safety in the discovery of 
therapies. The goal of setting up an animal model is to successfully predict an outcome in 
humans. However, perfect models for any disease rarely exist; weaknesses are present in 
each well-established model currently being used for skeletal disorders.  
Because of the low costs, fast growth, and the well-characterized skeletons, rats 
have historically been used as the most used laboratory animal for studies of 
osteoporosis. A study performed in 1985 observed that acute ovarian estrogen deficiency 
leads to dramatically increased cancellous bone turnover (Wronski, Lowry et al. 1985). 
Subsequent studies showed that ovariectomy (OVX) resulted in cortical and trabecular 
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bone loss, leading to the wide adoption of this model (Turner, Riggs et al. 1994). OVX 
rats trigger a series of cytokine reactions that mimic the postmenopausal status, thus 
stimulate bone resorption and lead to bone loss. Detailed mechanisms of estrogen 
deficiency had been described earlier (1.5.1.1 Mechanism of osteoporosis). However, the 
OVX model requires a complicated surgical procedure on each subject, which increases 
the cost and limits the practicality of this model. Besides the OVX models, rats had been 
also used as a model for disuse osteoporosis, which could be induced by unilateral sciatic 
nerve damage, tendonotomy, unilateral limb casting, hindlimb suspension or spaceflight 
(Morey and Baylink 1978; Turner and Bell 1986; Bateman, Zimmerman et al. 1998). All 
disuse models require surgery or other complicated procedures.  
Recent improvements on transgenic technology allow the purposeful 
manipulation of targeted gene expression, which had made mice another popular model 
for skeletal diseases. Many studies had used the techniques of specific knock-out or over-
expression of targeted genes in transgenic mice and greatly improved understanding of 
the mechanisms of bone remodeling and skeletal diseases. The roles of a series of key 
regulators in the skeletal system, such as M-CSF, RANKL, OPG, PTHrP, and PU-1, were 
either discovered or confirmed using transgenic mice (Felix, Cecchini et al. 1990; 
Lanske, Karaplis et al. 1996; Simonet, Lacey et al. 1997). However, drawbacks also exist 
while use transgenic mice as a disease model: Genes being specifically knocked-out or 
over-expressed are usually important in other systems besides the skeleton, thus many 
growth defects accompanied the skeletal abnormality in transgenic mice, which makes it 
difficult to mimic the pathological states. Furthermore, the development of a new 
transgenic mice model usually takes a long period of time.  
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Therefore, there is a need to develop novel animal models for skeletal diseases. 
Due to the unique role and functions of RANK/RANKL/OPG system in 
osteoclastogenesis, we have targeted RANKL, the final effector of osteoclastogenesis, as 
a specific agent for developing novel bone loss models. Study details will be presented in 
Chapter 4 of this project.  
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2.1 General Hypothesis 
As described in detail in Chapter One, previous studies have demonstrated the 
important role of M-CSF and RANKL on osteoclastgenesis. M-CSF stimulates the 
proliferation and early differentiation of osteoclast progenitors to osteoclast lineage, 
while RANKL targets the later stages of fusion and activation, and stimulates the 
formation of functional active osteoclasts (Figure 2.1). In this project, we hypothesized 
that while M-CSF and RANKL can both stimulate osteoclastogenesis, the 
differences in activation stages targeted by these two cytokines would result in 
distinct responses on bone biomechanics. RANKL would act as the final effector of 
osteoclastogenesis by directly stimulating osteoclast activity and increasing bone 
resorption. Alternately, M-CSF promotes the proliferation and differentiation of 
osteoclast progenitors but not the activation of mature osteoclasts, thus it has less 
influence on bone resorption but stimulates osteoblast development through the coupling 
of osteoclast-osteoblast cells, and may promote bone formation and increase bone 
















Figure 2.1 Osteoclastogenesis regulation 
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2.2 Specific Aims 
Aim 1: Examine the basic functional and biomechanical effects of RANKL 
administration on mouse bone density and quality. Hypothesis: Artificial RANKL 
administration is destructive to bone biomechanics. Approach: Mice received two 
different dosages of RANKL by twice daily injections for 10 days. Femora and tibiae 
were collected at sacrifice. Cortical and trabecular bone volume, bone mineral content, 
bone strength, and bone turnover markers were analyzed to evaluate the functional 
changes on bone induced by direct soluble RANKL injection. These experimental results 
are presented in Chapter 3.  
Aim 2: Develop a RANKL-induced bone destructive model for high-turnover 
osteolytic bone diseases. Hypothesis: Continuous infusion of metabolically relevant 
doses of RANKL in a mature rat model mimics deleterious skeletal changes in many 
osteolytic skeletal diseases. Approach: Six-month old rats received long term (28 days) 
RANKL infusion via osmotic pumps to create a skeletally mature bone loss model. Blood 
was collected at predetermined time points to examine changes in bone turnover markers 
rates by ELISA. Femurs and tibias were collected at sacrifice to evaluate the changes in 
volume, mineral content, geometry and strength. Aortas were also collected to evaluate 
the correlation of vascular calcification and RANKL induced bone loss. These 
experimental results are presented in Chapter 4. 
Aim 3: Characterize the effects of artificial M-CSF administration on the skeleton 
and determine its potential as an anabolic agent for bone biomechanics. Hypothesis: 
Activation of osteoclasts early in the differentiation cycle will have an anabolic, rather 
than catabolic, effect on skeletal properties. Approach: High dosages M-CSF were 
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administered to seven-week old mice for 3 weeks. Serum was collected at sacrifice to 
examine bone turnover markers levels. Femora and tibias were collected to evaluate the 
changes in volume, mineral content, geometry and strength. These experimental results 
are presented in Chapter 5. 
2.3 Clinical Significance 
Many skeletal diseases, such as osteoporosis, malignant bone metastases, and 
rheumatoid arthritis are generally osteolytic and associated with increased bone turnover 
rates and bone remodeling towards excessive resorption. Equilibrium of the regulation 
network is interrupted in these disease states, resulting in excessive osteoclast activity, 
bone loss, inferior bone architecture, and increased fracture risk. Within the complex 
cytokine environment, RANKL and M-CSF are critical for osteoclast differentiation and 
activation. RANKL is the final effector of osteoclast activation and bone resorption. 
Skeletal complications in osteolytic diseases are generally triggered by up-regulation of 
RANKL expression levels in the bone local environment. M-CSF plays an indispensable 
role in early osteoclast development. Mice with M-CSF gene knockout developed 
profound osteoporosis-opposite (osteopetrotic) phenotype with little or no osteoclast 
activity. 
It is evident that both RANKL and M-CSF are necessary for osteoclastogenesis. 
However, the impact of excessive levels of these two cytokines, resulting in activations 
of osteoclastogenesis at different stages, has not been fully characterized. The goal of this 
project is to further investigate the mechanism of critical cytokine regulation on 
osteoclastogenesis and subsequent biomechanical changes. Studies in this project have 
demonstrated the deleterious effects of elevated RANKL levels to bone biomechanics, 
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and suggested a novel bone loss animal model induced by RANKL for osteolytic skeletal 
disease research. Aim 3 of this project showed that M-CSF increased bone formation 
through coupled stimulating early osteoclastogenesis and osteoblast development, and 
indicated the potential of M-CSF as a novel anabolic agent for osteoporosis. Finally, 
Chapter 6 presents the conclusions and recommendation for future work. Data from this 







EXAMINATION OF RANKL AS A CRITICAL OSTEOCLASTOGENESIS 
STIMULATOR AND ITS FUNCTIONAL EFFECTS ON BONE DENSITY AND 
QUALITY 
Data related to this chapter has been submitted as a manuscript to Bone. Contents 
presented here are the manuscript formatted following dissertation requirements. 
3.1 Introduction 
Bone strength is determined by bone mass and bone quality (Ammann and Rizzoli 
2003; Heaney 2003). Bone mass reflects the balance between bone formation and bone 
resorption, which involves regulation of osteoblast and osteoclast numbers and activity at 
the cellular level. Moreover, bone formation and resorption is a coupled process: 
osteoblasts regulate the recruitment and activity of osteoclasts through expression of 
RANKL and OPG (Simonet, Lacey et al. 1997; Lacey, Timms et al. 1998). Balanced 
RANKL/OPG levels are critical for maintaining bone remodeling in a precise manner 
(Simonet, Lacey et al. 1997; Lacey, Timms et al. 1998; Hofbauer and Heufelder 2001; 
Khosla 2001). Bone quality is determined by a number of variables, including bone 
turnover, microarchitecture, microdamage, and degree of mineralization. Of these many 
determinants of bone quality, bone turnover is particularly important. Unnecessarily high 
bone turnover markedly degrades bone quality by disrupting the normal bone remodeling 
cycle (Turner 2002; Heaney 2003). For example, Paget’s disease in humans is 
 59
characterized by high bone turnover, rapid remodeling of woven bone, skeletal deformity, 
and fractures (Roodman and Windle 2005). 
RANKL (Receptor Activator of NF-κB Ligand), expressed by stromal cells and 
osteoblasts, is an essential mediator of osteoclast formation, activation, and survival 
(Lacey, Timms et al. 1998). RANKL binds to its receptor RANK on the surface of 
osteoclasts and their precursors; stimulates differentiation of osteoclastic precursors into 
mature osteoclasts; activates mature osteoclasts; and induces bone resorption (Lacey, 
Timms et al. 1998; Suda, Takahashi et al. 1999; Takahashi, Udagawa et al. 1999; Lacey, 
Tan et al. 2000). Osteoprotegerin (OPG), a member of the tumor necrosis factor-receptor 
superfamily, is a soluble decoy receptor for the ligand and blocks RANKL/RANK 
interactions (Simonet, Lacey et al. 1997; Kostenuik and Shalhoub 2001). Previous studies 
confirm this important role of the RANKL/OPG system. Transgenic mice overexpressing 
RANKL, and OPG-knockout mice (OPG-/-) each develop severe osteoporosis 
accompanied by increased osteoclast differentiation and activation, low bone mineral 
density, and high bone turnover (Lacey, Timms et al. 1998; Kostenuik and Shalhoub 
2001; Mizuno, Kanno et al. 2002). As these studies indicate, the amount of bone resorbed 
during the bone remodeling process is dictated by the balance between the expression of 
RANKL and its inhibitor, OPG. 
RANKL exists in both soluble and membrane-bound forms. Membrane-bound 
RANKL has been found to be a member of membrane-associated tumor necrosis factor 
family, expressed on the osteoblast/stromal cell surface (Lacey, Timms et al. 1998; 
Hofbauer and Heufelder 2001). Membrane-bound RANKL mediates bone resorption by 
binding to its receptor RANK through direct cell-to-cell interaction between osteoblasts 
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and osteoclasts (Yasuda, Shima et al. 1998). In cell co-culture systems, this cell-cell 
interaction appears to be essential for osteoclastogenesis and activation (Yasuda, Shima 
et al. 1998). However, soluble RANKL also induces osteoclastogenesis and bone 
resorption in cell culture systems (Lacey, Timms et al. 1998). In addition to its 
membrane-bound form, RANKL can be directly secreted from cells (Suzuki, Ikeda et al. 
2004), and can also be released from the surface of activated T cells (Mizuno, Kanno et 
al. 2002; Kanamaru, Iwai et al. 2004). Although previous in vitro studies suggest that 
membrane-bound RANKL is more potent than the soluble form in osteoclastogenesis 
development (Yasuda, Shima et al. 1998; Nakashima, Kobayashi et al. 2000), the 
contribution of each form on regulation of bone remodeling remains largely unknown. 
We hypothesized that the direct injection of soluble recombinant RANKL would 
recapitulate many of the skeletal changes that have been described in mice that lack the 
OPG gene, including deleterious effects on bone volume, geometry, density, and strength, 
and serve as an accelerated model for high-turnover bone disease such as post-
menopausal osteoporosis.  
3.2 Materials and Methods 
3.2.1 Study design 
Thirty-six female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) aged 10 
weeks were assigned to one of three groups: VEH (placebo control, phosphate buffered 
saline, n=12), LOW (0.4 mg/kg/day RANKL injection, n=12), HI (2 mg/kg/day RANKL 
injection, n=12). The form of human RANKL used in all studies comprised amino acids 
143-317, a region that includes the entire active ligand moiety distal to the extracellular 
cleavage site, as previously described (Lacey, Timms et al. 1998).  This construct, which 
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lacks transmembrane and intracellular domains, was expressed in Chinese Hamster 
Ovary (CHO) cells and purified at Amgen.  The purified protein had a molecular weight 
of 27 kD. All mice received twice daily subcutaneous injections (0.2ml per injection) for 
10 days. Body weights were monitored every two days, and drug concentrations were 
adjusted accordingly. Calcein (20 mg/kg) was injected (i.p.) as a fluorescent label at Day 
2 to monitor new bone growth. At Day 10, animals were anesthetized with isoflurane and 
euthanized by exsanguination followed by cervical dislocation. Both hind limbs were 
removed and cleaned of all nonosseous tissue. All procedures performed throughout the 
experiment conformed to the guidelines of Clemson University’s Institutional Animal 




Daily Injections (10 days):
- Saline (VEH)
- RANKL (0.4mg/kg, LOW)
- RANKL (2mg/kg, HI)





































Figure 3.1 Flowchart illustrating study design of the in vivo characterization of RANKL on bone 
biomechanics.  
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3.2.2 Serum bone-turnover markers 
Serum was obtained at sacrifice, and markers for bone formation and resorption 
were measured. Serum alkaline phosphatase (ALP) and total calcium levels were 
measured by an automated chemistry analyzer (Hitachi) as markers of bone formation 
and hypercalcemia, respectively. As a bone resorption marker, serum TRAP-5b was 
measured by ELISA (SBA Science/IDS Inc.). 
3.2.3 Micro CT 
Microcomputed tomography analysis (µCT20, Scanco Medical AG, Bassersdorf, 
Switzerland) with a voxel size of 9 µm in all three spatial dimensions was used to obtain 
both cortical and trabecular parameters (Ruegsegger, Koller et al. 1996; Dufresne 1998). 
Right femora were air-dried prior to the scan. Cortical bone parameters were obtained by 
scanning an 8 mm section of the femoral diaphysis (Figure 3.2), the same span length 
examined by mechanical testing. A total of 81 slices were analyzed, with 100µm 
increment lengths between slices. To determine bone volume and polar moment of 
inertia, contours were traced at the periosteal surface and calculated by Scanco IPL-
Moment software. To quantify the porosity of femoral cortical bone, two contours were 
traced on the periosteal and endocortical surfaces of each slice and evaluated by Scanco 
software. During evaluation, femur diaphysis was separated into three sections: proximal 
diaphysis (2.5mm in length, slices taken from the third trochanter), mid-diaphysis (3mm 
long), and distal diaphysis (2.5mm long, slices taken from the metaphysis). Porosity data 
were obtained from each of these sections. 
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Figure 3.2 3D microCT picture of an 8-mm long femur diaphysis 
Right tibiae were fixed in 10% neural buffered formalin for 2 days, rinsed with 
distilled water, and stored in 70% ethanol. Trabecular bone parameters were obtained by 
microCT scan of 0.9 mm sections of trabecular bone at the proximal end of the tibia, 
immediately distal to the growth plate (Figure 3.3). These parameters included trabecular 
bone volume (BV), total volume (TV), percent connectivity of trabecular struts, and 
trabecular volume fraction (BV/TV). 
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Figure 3.3 2-D cross-sectional picture on mouse proximal tibia showing the growth plate and 
trabecular bones 
3.2.4 Biomechanical testing 
Mechanical properties of right femora were tested following microCT analysis. 
All bones were rehydrated in phosphate-buffered saline (PBS) for 1.5 hours prior to 
mechanical testing to simulate in vivo properties (Broz, Simske et al. 1993). Three-point 
bending tests were performed using an Instron 5582 (Merlin, Series IX software). Femora 
were tested to failure with an 8 mm span length and deflection rate of 5mm/min (Figure 
3.4). Force (N) and deflection (mm) were measured at the elastic limit (Pe, δe), maximum 




Figure 3.4 Three point bending test on mid-femur with 8 mm span length 
3.2.5 Mineral content analysis 
Mineral content analysis was performed on the fractured femur. Prior to analysis, 
epiphyses at both proximal and distal ends were separated. Mineral-content data were 
obtained separately from epiphysis and diaphysis. Dry mass (Dry-M) was measured after 
heating the bones for 24 h at 105ºC. Mineral mass (Min-M) was measured after the bones 
had been ashed by baking for another 24 h at 800ºC. Percent mineralization (%Min) was 
calculated by the formula % Min = Min-M/Dry-M * 100%.  
3.2.6 Quantitative histomorphometry 
Left femora were placed in 10% neutral-buffered formalin for 48 hours and then 
stored in ethanol after being rinsed with distilled water. Bones were then allowed to air-
dry and embedded with noninfiltrating Epo-Kwick epoxy (Buehler, Lake Bluff, IL). The 
formed disks were sectioned with a low-speed saw (Buehler, 12.7cm x 0.5mm diamond 
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blade) at the mid-diaphysis of the femur. The sections were wheel-polished to a flat, 
smooth surface using 600-, 800-, and 1200-grit carbide paper followed by polishing with 
a cloth impregnated with 6 µm diamond paste. This allowed micrographs at 50X 
magnification to be taken of the bone cross-sections under a far blue light (400 nm). 
Green calcein labels were visualized, indicating the bone formation sites during the 
period of the study (Figure 3.5). Quantitative histomorphometric analysis was performed 
using these photographs and SigmaScan Pro software (SPSS, San Rafael, CA).  
Measurements of bone morphology (Parfitt, Drezner et al. 1987) included total 
bone area (T.Ar) enclosed by periosteal perimeter and endocortical area (Ec.Ar). Cortical 
area was calculated as T.Ar – Ec.Ar. A calcein label was injected at Day 2 of the study; 
the area between the labels and the cortical perimeter was measured as bone formation 
area (BFA), and linear content of the labeled perimeter was defined as active 
mineralizing perimeter (aMPm). Bone-formation rates were calculated as BFR = BFA/8 
days and mineral apposition rate as MAR = BFR/aMPm separately in the periosteal 
(Ps.BFR, Ps.MAR) and endocortical (Ec.BFR, Ps.MAR) areas. Endocortical-bone 
resorption perimeter (Ec.Rs.Pm) was also measured by quantifying the portion of the 
nonlabeled surface with rough/ruffled border.  
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Figure 3.5 2 D cross-sectional picture on mouse mid-femur showing fluorescent calcein labels 
under Ultraviolet (UV) microscope 
3.2.7 Statistics 
Statistical comparisons were performed using repeated measures of analysis of 
variance (ANOVA) with SigmaStat software. One-way ANOVAs, with a Tukey test for 
follow-up comparisons, were used. A 95% level of significance (type I error) was used 
for each of these tests. The correlation between serum TRAP-5b levels and bone strength 
was obtained from Pearson Product Moment Correlation test with SigmaStat. Data are 
presented as mean + standard error (SE). 
3.3 Results 
3.3.1 Weight loss and hypercalcemia 
Mice treated with saline or 0.4 mg/kg RANKL maintained normal body mass and 
blood calcium levels during the 10-day study. In HI group, an 11% weight loss was 
observed at the day of sacrifice (p<0.001, Figure 3.6); this was accompanied by 
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hypercalcemia symptoms, such as lethargy. Total serum calcium levels increased by 15.7 
% in HI group (p<0.001 vs. VEH), while a 20.3% increase was observed in serum 
phosphorus levels for HI group (p<0.001) compared to VEH, while those in LOW group 


























Figure 3.6 Body mass in the HI group decreased by 11% at sacrifice when compared to body 
























































Figure 3.7 Total serum calcium levels (A) increased by 15.7 % in HI group (p<0.001 vs. VEH). 
A 20.3% increase was observed in serum phosphorus levels (B) for HI group (p<0.001) compared 
to VEH, while those in LOW group remained unchanged. 
 71
3.3.2 Bone turnover 
Bone turnover rates were greatly accelerated by 10-day treatment of RANKL in 
both doses. The bone formation marker serum alkaline phosphatase levels (ALP) 
increased 224% and 321% in mice treated with low- and high-dose RANKL, respectively 
(p<0.001) vs. VEH. The bone resorption marker serum TRAP-5b was increased by 
83.8% and 49.2% (p<0.05) in LOW and HI group mice, respectively, relative to VEH 






































Figure 3.8 RANKL increased bone turnover rates. (A) Serum TRAP-5b levels were accelerated 
by 83.8% and 49.2% in low-and high-dose RANKL mice (p<0.05 vs. VEH). (B) Serum alkaline 
phosphatase levels increased 3-fold in 0.4mg/kg RANKL (LOW) and 4-fold in 2.0mg/kg 
RANKIL (HI) mice after 10 days of twice daily injections (p<0.001 vs. VEH). Data are presented 
as the mean ± SE. * = significantly different from VEH.  
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3.3.3 Cortical bone strength 
Both doses of RANKL reduced femur maximum strength, fracture strength, and 
stiffness. Maximum bending loads of femoral diaphyses were reduced by 25% (LOW) 
and 19% (HI), while structural stiffness was decreased by 38.5% (LOW) and 37.4% (HI) 
vs. VEH (p<0.001, Figure 3.9). In the HI group, serum TRAP-5b levels showed a 
negative correlation with maximum strength of the femur (r= -0.74, p=0.01, Figure 
3.10A), while serum ALP levels showed a positive correlation with maximum strength 





















































































Figure 3.9 Bone maximum bending strength was significantly reduced in RANKL groups, by 
19% to 25% (B), after 10 days of RANKL treatment (p<0.001). Femur stiffness (D) was 
decreased by 38.5% and 37.4% in low-and high-RANKL groups (p<0.001), respectively. In both 
RANKL treatment groups, there is a decreasing trend in elastic force (p=0.098, A) and fracture 
force (C, p=0.014 Low, p=0.102 in high dose group) compared to VEH. Data are presented as the 
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Figure 3.10 Serum TRAP-5b levels (A) negatively correlated to femur maximum strength with 
correlation coefficient r= -0.74 (p=0.01), while serum ALP levels (B) showed a positive 
correlation with maximum strength (r= 0.68, p=0.02). 
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3.3.4 Bone mineral content 
Whole femur dry mass measured from LOW and HI groups were significantly 
lower than VEH (12.2% and 15.9% respectively; p<0.001). The reduction in BMC at the 
epiphysis was greater than in the diaphysis. In the femoral epiphyses, reduction of dry 
mass in HI group was 9.9% greater than LOW (P<0.05). The outcome observed in 
mineral mass was similar. A dose-dependent decrease in femoral epiphyses was observed 
in LOW and HI groups. As a result, femur total percent mineralization was decreased by 
5.9% and 6.8% (p<0.05 vs. VEH), while the decrease in femur epiphyses was 8.9% and 


































Figure 3.11 RANKL reduced percent mineralization in mice femur. (A) No significant difference 
in percent mineralization was observed at femur diaphysis. (B) Femur epiphysis %Min was 
decreased by 8.9% and 12.5% in LOW and HI groups (p<0.001), respectively. Dose-dependence 
manner was observed: Higher dose of RANKL induced lower %Min than lower dosage (p<0.05). 
(C) Femur total %Min was decreased by 5.9% and 6.8% (p<0.05) by low and hi dose of RANKL. 
Data are presented as the mean ± SE. * = significant difference compared to VEH.  
3.3.5 Bone volumes indicated by MicroCT 
Cortical bone parameters were measured and calculated in an 8 mm span of the 
femur diaphysis. Moment of inertia at the mid-femur remained unchanged between 
groups (Figure 3.12). Cortical bone volumes from LOW and HI groups were significantly 
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lower than VEH (12.5% and 9.4% respectively; p<0.001, Figure 3.13A). Trabecular 
parameters were measured from a 0.9 mm thick section of trabecular bone in proximal 
tibia. Trabecular volume fraction (BV/TV) was decreased drastically, by 85%, in both 












Figure 3.12 No differences were observed in polar moment of inertia at femur mid-diaphysis. 











































Figure 3.13 RANKL reduced both cortical and trabecular bone volume. (A) Cortical bone 
volume was measured and calculated in an 8-mm section of femur diaphysis. RANKL 
significantly reduced cortical bone volume by 13% and 10% in low-and high-dose RANKL 
groups (p<0.001 vs. VEH). (B) Trabecular bone parameters were measured from a 0.9mm section 
of trabecular bone at proximal tibia. RANKL drastically reduced trabecular bone fraction 
(BV/TV) in both treatment groups by 85% (p<0.001 vs. VEH). Data are presented as the mean ± 
SE. * = significant difference between VEH. 
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VEH LOW HI
Figure 3.14 3D microCT pictures of 2-mm sections of trabecular bone at proximal tibia illustrate 
severe bone loss induced by RANKL. 
3.3.6 Quantitative histomorphometry 
Quantitative histomorphometric analysis (Table 3.1) of the femur mid-diaphysis 
revealed that endocortical bone resorption was sharply increased in both RANKL 
treatment groups. Endocortical area was increased by 8.9% and 7.8% (p<0.05) in LOW 
and HI groups, respectively, due to the increase in bone resorption at the endocortical 
surface; this is evidenced by greater endocortical resorption perimeters of 83% and 79% 
in LOW and HI groups, respectively. This increase in resorption led to a decrease of 
cortical area of 6.3% and 7.8% in LOW and HI groups (p<0.05), respectively. 
RANKL increased cortical bone turnover rate, as evidenced by significant 
elevations of periosteal bone-formation rate with low-dose (87.3%, p<0.001) and high-
dose RANKL (63.9%, p<0.05) versus VEH. Increases in endocortical bone formation 
rates were not observed, perhaps because bone resorption on this surface was sufficiently 
robust to remove the fluorochrome label. Consistently, active mineralizing perimeters 
were increased for the periosteal surface (p<0.05) but decreased at the endocortical 
surface (p<0.001). Similarly, RANKL increased mineral apposition rates in both 
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periosteal and endocortical surfaces, leading to an increase of 33% (p<0.001) and 23% 
(p<0.05) in LOW and HI groups, respectively. Because of the increase in periosteal bone 
formation and endosteal bone resorption, no significant change was observed in polar 
moment of inertia of the femur diaphysis. 
Table 3.1 Quantitative histomorphometry at femur mid-diaphysis: Measurements were taken 
from the UV microscope photographs of the mid-diaphysis cross section. Ec = endocortical, Ps = 
periosteal, Tt = total, Ar = area, B = bone, BFR = bone formation rate, aMPm = active 
mineralizing perimeter, MAR = mineral apposition rate, Ec.Rs.Pm = endocortical resorption 
perimeter, pMOI = polar moment of inertia at mid-diaphysis. Data are presented as mean ± SE. *: 
data are significantly different vs. VEH at p<0.001. #: data are significantly different vs. VEH at 
p<0.05. a: p=0.07, b: p=0.06, c: p=0.08. 
 
RANKL treated Measurement Vehicle 
0.4 mg/kg (Low) 2 mg/kg (Hi) 
Ec.Ar. (mm2) 0.90 ± 0.01 0.98 ± 0.02# 0.97 ± 0.01# 
Ct. Ar (mm2) 0.64 ± 0.02 0.60 ± 0.01# 0.59 ± 0.01# 
Tt.B.Ar (mm2) 1.55 ± 0.02 1.57 ± 0.02  1.56 ± 0.01  
Ct.Th (mm) 0.151 ± 0.004 0.136 ± 0.002# 0.135 ± 0.002# 
Ec.BFR (10-3 mm2/day) 3.76 ± 0.30 2.96 ± 0.14# 3.09 ± 0.32  
Ps.BFR (10-3 mm2/day) 1.66 ± 0.18 3.11 ± 0.33* 2.72 ± 0.21# 
Tt.BFR (10-3 mm2/day) 5.42 ± 0.36 6.07 ± 0.39 5.81 ± 0.41 
Ec.aMPm (mm) 2.24 ± 0.15 1.44 ± 0.05* 1.56 ± 0.13* 
Ps.aMPm (mm) 1.14 ± 0.05 1.39 ± 0.10# 1.37 ± 0.05 a 
Tt. aMPm (mm) 3.38 ± 0.17 2.83 ± 0.12# 2.93 ± 0.10 b 
Ec.MAR (10-3 mm/day) 1.68 ± 0.10 2.06 ± 0.07# 1.96 ± 0.11 c 
Ps.MAR (10-3 mm/day) 1.42 ± 0.11 2.15 ± 0.17* 1.96 ± 0.11# 
Tt.MAR (10-3 mm/day) 1.60 ± 0.07 2.13 ± 0.09* 1.97 ± 0.10# 






3.3.7 Femur diaphysis cortical porosity 
Cortical porosity at the femur diaphysis was increased by 25.9% and 45.1% in 
LOW and HI groups (p<0.001) vs. VEH.  By separating the femur diaphysis into 
proximal diaphysis, mid-diaphysis, and distal diaphysis, we found that RANKL had 
differential effects on these sites (Figure 3.15). Pore size and number at the trochanter 
(proximal) were increased in both LOW and HI groups, resulting in 54.8% and 82% 
increase of porosity (p<0.001) vs. VEH. In the distal femur, porosity was increased by 
38.6% in HI group (p<0.001); the change in LOW was not significant. There was a trend 
towards increased porosity at mid-diaphysis in both RANKL groups (p=0.08) compared 



























































Figure 3.15 RANKL increased cortical porosity at the femur diaphysis. By dividing the femur 
diaphysis (8mm long scan area) to distal diaphysis (distal 2.5mm), mid-diaphysis (middle 3mm) 
and proximal diaphysis (proximal 2.5mm), we observed different effects on different sites of 
femur. (A) At distal femur, high dose RANKL caused an increase of 38.6% in porosity; the 
change in the low-dose RANKL group was not significant. (B) There was a trend of increased 
porosity at mid-diaphysis (p=0.08) by both doses of RANKL. (C) Both low and hi dose of 
RANKL increased porosity at the proximal diaphysis (trochanter) by 54.8% and 82% in LOW 
and HI groups, respectively. (D) Whole femur cortical porosity was increased by 25.9% and 
45.1% in LOW and HI groups. Data are presented as mean ± SE. * = p<0.001 vs. VEH. # = 








Figure 3.16 2-D microCT images from 4mm to plateau (A) and 2mm to plateau (B) at proximal 
tibia were taken to demonstrate cortical porosity. 
Cortical porosity at the total femur diaphysis was examined for correlations. It 
was observed to be associated with reduced bone strength, as shown by a negative 
correlation between porosity in the HI group and the maximum strength of the femur (R= 
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Figure 3.17 In the HI group, whole femur porosity negatively correlated to femur maximum 
strength with correlation coefficient r= -0.76 (p= 0.007). 
3.4 Discussion 
High bone turnover is thought to contribute to fracture incidence in 
postmenopausal osteoporosis subjects (Hochberg, Greenspan et al. 2002). One potential 
etiological factor in the high turnover state of postmenopausal osteoporosis is RANKL 
(Eghbali-Fatourechi, Khosla et al. 2003), a TNF family member that is essential for 
osteoclast formation, function and survival (Lacey, Timms et al. 1998; Lacey, Tan et al. 
2000). There are numerous animal models for studying the impact of high-turnover bone 
disease on bone quality and bone strength, and ovariectomy (OVX) is the most 
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commonly used. OVX recapitulates many of the important skeletal changes associated 
with postmenopausal osteoporosis, including increased osteoclast and osteoblast 
numbers, reduced bone volume and density, and decreased strength of trabecular sites 
such as the lumbar vertebrae (Kostenuik, Capparelli et al. 2001; Kostenuik, Bolon et al. 
2004). While postmenopausal osteoporosis is associated with increased fracture incidence 
at both cortical and cancellous sites, OVX does not consistently result in reductions in 
cortical bone strength in mice or rats. We have used soluble RANKL to develop a new 
animal model of high-turnover bone disease that recapitulates many of the deleterious 
skeletal changes associated with postmenopausal osteoporosis, including a reduction in 
the strength of cortical bone. Advantages of this model include its rapidity (10 days) and 
the lack of surgical intervention. 
There are limited data on the direct catabolic effects of RANKL on bone. Short-
term (3-day) injection of RANKL resulted in reduced cancellous bone volume and 
hypercalcemia (Lacey, Timms et al. 1998), but the effects of RANKL injections on bone 
mineralization, formation, geometry, and strength have not been previously described. In 
an isolated report, the overexpression of soluble RANKL in transgenic mice was shown 
to increase bone turnover and reduce bone density and femur strength, suggesting that 
continuous exposure to excess RANKL can mimic some of the cortical changes 
associated with postmenopausal osteoporosis (Mizuno, Kanno et al. 2002). However, the 
skeletal changes in these mice are partially related to overexpression of RANKL during 
the early growth and development of the skeleton, which would limit the utility of these 
mice as a model of postmenopausal osteoporosis. In contrast, the direct injection of 
soluble RANKL can create osteoporosis-like changes that can be monitored over a short 
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period of time in young or adult animals. An interesting observation with RANKL 
transgenic mice was that the skeletal phenotype appeared to be less severe than the 
phenotype associated with OPG knockout mice. This could imply that the local and 
systemic absence of the endogenous RANKL inhibitor OPG results in skeletal changes 
that cannot be mimicked by systemic exposure to soluble RANKL. Alternatively, 
transgene expression may have been too modest in these animals to fully overcome the 
local inhibitory effects of OPG. The latter possibility is supported by the current data, 
wherein the direct injection of high doses of soluble RANKL created a skeletal 
phenotype that was very similar to that associated with the total ablation of OPG (Bucay, 
Sarosi et al. 1998; Mizuno, Amizuka et al. 1998; Min, Morony et al. 2000; Nakamura, 
Udagawa et al. 2003). The phenotypic similarities included increased serum alkaline 
phosphatase, decreased bone volume and density, reduced mineralization, increased 
cortical porosity and reduced strength.  
The ability of soluble RANKL to increase local and systemic bone resorption 
parameters was shown by increases in endocortical resorption, cortical porosity, and 
serum TRAP-5b (a specific marker of osteoclasts).  While intracortical remodeling is not 
a common finding in mice, it appears that excessive RANKL activity can lead to this 
pathologic change.  The strong negative correlation between cortical porosity and bone 
strength suggests a possible mechanism by which excessive RANKL activity might 
contribute to reduced cortical bone quality and strength. 
Increased endocortical bone resorption perimeter was associated with an enlarged 
medullar cavity and a decrease in cortical area and thickness. These results are consistent 
with the previous finding that OPG knockout mice have increased endocortical osteoclast 
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surface, which was reversed by the transgenic overexpression of soluble OPG (Min, 
Morony et al. 2000). Another negative consequence of high bone turnover is an increase 
in cortical porosity. Increased cortical porosity appears to account for a substantial age-
related decline in bone strength (McCalden, McGeough et al. 1993), and cortical porosity 
in hip fracture cases shows a distinct regional (non-homogenous) distribution (Bell, 
Loveridge et al. 1999). In our study, administration of RANKL induced cortical porosity 
of the femur by increasing both the size and number of pores. Cortical porosity was 
region-specific, with significant increases observed in the proximal and distal metaphyses 
of the femoral diaphysis but not the mid-diaphysis. Despite the lack of porosity at the 
mid-diaphysis, bone strength at this location was reduced by RANKL based on 3-point 
bending tests that created mid-shaft fractures. This location was associated with increased 
endocortical area and reduced cortical thickness, area and volume, which were likely 
contributors to the observed reduction in bone strength. The potential contribution of 
porosity to reduced bone strength at the distal and proximal femur shaft was not 
determined, and would be better studied in larger species such as the rat. Compositional 
analysis data of the femora revealed reduced mineralization with RANKL injections. The 
dose-dependent reduction in percent mineralization was more significant in trabecular 
bone than in cortical bone, suggesting changes in materials properties in addition to 
structural changes described.  
Previous studies have shown that markers of bone formation (e.g. serum alkaline 
phosphatase) tend to increase following periods of bone resorption, due to the normal 
physiological coupling between osteoblasts and osteoclasts (Bucay, Sarosi et al. 1998; 
Nakamura, Udagawa et al. 2003). In this study, RANKL injections increased local and 
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systemic bone formation paramaters, as indicated by a 3- to 4-fold increase in serum ALP 
levels and a significant increase in periosteal bone formation rate. The increase in bone 
formation is likely related to normal physiological coupling, a process that is preserved in 
settings of RANKL inhibition (Nakamura, Udagawa et al. 2003). Our data suggest that 
excessive RANKL also leads to a coupling-related increase in bone formation. While 
positive, the compensatory effect of RANKL on periosteal bone formation was 
apparently insufficient to counteract deleterious effects on endocortical area and cortical 
thickness, area and volume. These cortical changes are somewhat reminiscent of changes 
that were recently described in a longitudinal analysis of cortical bone geometry in 
subjects with postmenopausal osteoporosis (Ahlborg, Johnell et al. 2003). Menopause 
was accompanied by a progressive decrease in femur BMD and an increase in 
endocortical diameter, while periosteal diameter increased over time. It was proposed that 
this periosteal expansion may occur as a naturally reaction to the menopause-related 
decline in BMD and increase in endocortical resorption (Ahlborg, Johnell et al. 2003). In 
our study, increased periosteal bone formation may have contributed to the maintenance 
of a normal polar moment of inertia at the femur diaphysis, despite the increase in 
endocortical area. This constructive periosteal response may have helped to limit the loss 
of cortical bone strength associated with RANKL injections, but longer-term follow up 
would be required to determine if absolute periosteal expansion occurs in association 
with RANKL injections and if the new bone is of a competent nature with appropriate 
material properties. 
This study has some limitations, including the lack of an obvious dose-response 
for many of the endpoints. We believe that a lower dose range would have provided a 
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clearer dose response for the majority of parameters. Dose-dependent weight loss and 
hypercalcemia are consistent with the notion that the twice-daily injection of RANKL at 
2 mg/kg was an excessive dose that resulted in toxicity. It remains possible that a once-
daily dose of RANKL at 0.4 mg/kg or lower could recapitulate many of the deleterious 
skeletal effects we describe with twice-daily dosing, but without signs of the harmful 
response. Another limitation is that we did not study changes in cancellous bone 
compartments, primarily because mice have modest cancellous bone volume and the 
biomechanical testing of mouse vertebrae is challenging. Rat studies would be a preferred 
model for characterizing the effects of RANKL on cancellous bone, and preliminary data 
have been recently described (Yuan, Kostenuik et al. 2006 (Abstract)).  
3.5 Conclusions 
In this study, we have demonstrated that the direct injection of soluble 
recombinant RANKL levels caused severe and rapid catabolic effects on both trabecular 
and cortical bone. These effects include increased bone resorption, reduction of cortical 
and trabecular mineral content, reduction of cortical and trabecular bone volume, increase 
in cortical bone porosity, and reduction of cortical bone strength. These data establish a 
new non-surgical model for rapid bone loss in mice, which is characterized by cortical 
and cancellous changes that are similar to those associated with OPG gene ablation and 
more severe than those associated with ovariectomy. The ability of systemic RANKL 
injections to mediate these changes suggests that soluble RANKL could be involved in 
pathologic bone loss, although further studies are clearly needed to evaluate the relative 
role of soluble versus membrane RANKL in the regulation of bone resorption. This 
model may be relevant for bone loss initiated by local and/or systemic changes that are 
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associated with osteoporosis and joint destruction associated with inflammation (Kong, 
Feige et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003).  
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RANKL INFUSION AS A DISEASE MODEL: INDICATIONS ON SKELETAL 
DETERIORATION 
Data related to this chapter has been submitted as a manuscript to Journal of Bone 




Bone remodeling is a continuous lifelong process that plays an important role in 
regulating bone structure and function.  Bone remodeling is homeostatic when the 
amount of bone resorbed during each remodeling cycle is matched by subsequent bone 
formation and refilling of the remodeling site.  Bone resorption exceeds bone formation 
in many pathological states, leading to net bone loss, inferior bone architecture, and 
increased fracture risk (Coleman 1997; Hofbauer and Schoppet 2004; Blair, Zhou et al. 
2006). The bone remodeling process is regulated by a variety of hormones and cytokines 
(Teitelbaum 2000; Boyle, Simonet et al. 2003), including parathyroid hormone (PTH), 
interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), transforming growth factor β 
(TGF-β), vitamin D3, and macrophage colony stimulating factor (M-CSF) (Suda, 
Takahashi et al. 1999; Teitelbaum 2000; Boyle, Simonet et al. 2003; Zaidi, Blair et al. 
2003). The initiation of bone remodeling requires the presence and activity of RANKL 
(Receptor Activator of Nuclear Factor κB Ligand) (Morony, Capparelli et al. 1999).  
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RANKL is a member of TNF superfamily that is expressed by osteoblasts (Fuller, Wong 
et al. 1998), bone marrow stromal cells (Eghbali-Fatourechi, Khosla et al. 2003), and 
activated T-cells (Anderson, Maraskovsky et al. 1997). RANKL stimulates bone 
resorption by binding to its receptor, RANK, on the surface of osteoclasts and their 
precursors, thereby promoting osteoclast formation, function and survival (Lacey, Timms 
et al. 1998; Yasuda, Shima et al. 1998).  OPG is a soluble decoy receptor for RANKL, 
and its binding to RANKL inhibits bone resorption and prevents bone loss by preventing 
RANKL-RANK interactions (Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997).  
The RANKL:OPG ratio might represent a potentially important determinant of 
bone remodeling (Nagai and Sato 1999; Fazzalari, Kuliwaba et al. 2001), and an 
increased RANKL:OPG ratio is evident in various bone diseases (Haynes, Crotti et al. 
2001; Grimaud, Soubigou et al. 2003; Stilgren, Rettmer et al. 2004).  Estrogen deficiency 
in postmenopausal women is associated with enhanced RANKL expression by stromal 
cells and T cells, and low bone mineral density (Eghbali-Fatourechi, Khosla et al. 2003). 
In an inflammatory environment, such as in rheumatoid arthritis, cytokines released by 
the immune cells increase the RANKL/OPG ratio and lead to joint destruction and bone 
loss (Kong, Feige et al. 1999; Lubberts, van den Bersselaar et al. 2003; Stolina, Adamu et 
al. 2005). RANKL also plays an important role in malignant diseases, such as multiple 
myeloma and osteolytic bone metastases. Myeloma cells enhance RANKL release and 
down-regulate OPG expression, thereby increasing bone resorption and promoting bone 
loss (Giuliani, Bataille et al. 2001; Standal, Seidel et al. 2002). In osteolytic bone 
metastases, such as breast and lung cancer, tumor cells directly express RANKL and/or 
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indirectly increase RANKL levels through expression of PTH related peptide (PTHrP), 
resulting in bone lesions (Michigami, Ihara-Watanabe et al. 2001; Mundy 2002).  
There are at least 3 isoforms of RANKL, including membrane-bound and soluble 
forms.  The membrane-bound form is the likely candidate for mediating osteoclastogenic 
responses that require cell-cell contact in certain co-culture systems (Fuller, Gallagher et 
al. 1991).  The soluble forms of RANKL are either directly secreted, or enzymatically 
cleaved from the cell surface (Ikeda, Kasai et al. 2001; Suzuki, Ikeda et al. 2004).  The 
relative contribution of soluble versus membrane-bound RANKL to bone turnover is 
unclear, and may differ with normal versus pathological bone remodeling.  Increased 
soluble RANKL was observed in the serum of animals with high-turnover bone disease 
associated with inflammatory arthritis (Stolina, Adamu et al. 2005).  Increased serum 
RANKL was also reported in patients with high-turnover bone disease (Franchimont, 
Reenaers et al. 2004; Morabito, Gaudio et al. 2004; Avbersek-Luznik, Balon et al. 2005; 
Geusens, Landewe et al. 2006; Kim, Kim et al. 2006).  Reports of upregulated membrane 
RANKL are sporadic, perhaps due to the more cumbersome nature of such analyses 
compared to ELISA-based serum assays.  In one example, postmenopausal subjects 
showed higher levels of RANKL on the surface of bone marrow cells compared to 
premenopausal subjects, while no menopause-related differences in soluble RANKL 
were observed in peripheral blood(Eghbali-Fatourechi, Khosla et al. 2003).  Circulating 
levels of soluble RANKL are very low, and are frequently below the detection limits of 
presently available ELISA assays (Abrahamsen, Hjelmborg et al. 2005).  It remains 
unclear as to whether changes in serum RANKL are reflective of changes found within 
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bone, which further confounds attempts to deduce from observational studies the 
potential consequences of excessive RANKL on bone.   
To study the skeletal pathologies associated with increased RANKL levels, we 
created an animal model using normal rats exposed to four-week continuous 
administration of soluble human RANKL via osmotic pumps. We hypothesized that 
excessive RANKL levels would create a spectrum of skeletal changes that are typically 
associated with high-turnover bone loss conditions, including reduced bone mass, density 
and strength in association with the deterioration of cancellous bone architecture and 
cortical bone geometry.  The RANKL/OPG system has also been implicated in vascular 
disease, as evidenced by the development of arterial calcification in OPG deficient mice 
(Min, Morony et al. 2000).  We therefore harvested aortas at the end of the study to 
evaluate mineral content as a surrogate for vascular calcification.   
4.2 Materials and Methods 
4.2.1 Study design 
The form of human RANKL used in all studies comprised amino acids 143-317, a 
region that includes the entire active ligand moiety distal to the extracellular cleavage 
site, as previously described (Lacey, Timms et al. 1998).  This construct, which lacks 
transmembrane and intracellular domains, was expressed in Chinese hamster ovary 
(CHO) cells and purified at Amgen.  The purified protein had a molecular weight of 27 
kD. A pilot study was performed to determine safe, effective doses for continuous 
RANKL administration to rats. Twenty Sprague-Dawley (SD, Harlan, Indianapolis) rats 
six months of age were assigned to five groups of four rats per group. Alzet osmotic 
pumps (2ML2) implanted subcutaneously in the rats for 14 days administered RANKL at 
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10, 50, 100, 200, and 400 µg/kg/day dosages. Blood was collected daily from each 
specimen via the saphenous vein to examine ionized calcium levels. The two highest 
doses of RANKL led to significant and dose-dependent hypercalcemia (Figure 4.1), with 
the 200 µg/kg/day rats recovering weight loss relatively quickly (data not shown), 
indicating that this dosage has less toxicity.  We therefore selected a lower dose of 175 
ug/kg/day as the highest dose to study skeletal catabolism, as well as a 5-fold lower one 
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Figure 4.1 Five groups of SD rats (n=4) received 14 days RANKL infusion at 10, 50, 100, 200 
and 400 µg/kg/day dosages in the pilot study. Blood was collected daily, and ionized-calcium 
levels were examined as the efficacy indicator for RANKL administration. Rats treated with 200 
and 400 µg/kg/day RANKL experienced a significant hypercalcemia, which recovered to baseline 
level at the end of the study. Data are presented as the mean ± SE. 
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For the main study, 36 male SD rats approximately 6 months of age were 
assigned to 3 groups: VEH (Vehicle control, phosphate buffered saline, n=12), LOW 
(low dose RANKL, 35 µg/kg/day, n=12) and HI (high dose RANKL, 175 µg/kg/day, 
n=12).  On Day 0, surgeries were performed to insert the osmotic pumps (Alzet 2ML4) 
subcutaneously (dorsal region) into the rats (Figure 4.2). Treatments were delivered at a 
constant rate of 2.5 µl per hour in the body environment for 28 days. Injection of 20 
mg/kg calcein (i.p.) at days 2 and 26 provided fluorescent labels to monitor new bone 
growth. To achieve serial serum data, blood was collected intermittently at Days 0, 3, 7, 
14, and 21 from the saphenous vein and at Day 28 via cardiac puncture and 
exsanguination. 
 
Figure 4.2 Diagram of Alzet osmotic pumps for drug delivery 
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At sacrifice, pumps were removed and residual drug volumes were checked to 
ensure drug delivery. Hind limbs were collected and cleaned of all non-osseous tissue; 
and the arterial trunks dissected. Throughout the experiment, all procedures conformed to 
the guidelines of Clemson University’s Institutional Animal Care and Use Committee 
(Figure 4.3). 
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Main Study (Thirty-Six Rats)
Continuous Administration (28 Days):
- Saline (VEH)
- RANKL (35 g/kg, LOW)
- RANKL (175 g/kg, HI)




















































Figure 4.3 Flowchart illustrating the study design of the RANKL infusion study 
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4.2.2 Serum bone-turnover markers 
Serum was collected at the time points identified. Osteocalcin and TRAP-5b were 
measured by ELISA (SBA Science/IDS Inc.) as bone formation and resorption markers, 
respectively. Human RANKL levels were quantified via ELISA on Day 28, using an 
ELISA kit (SBA Science/IDS Inc.).  
4.2.3 Micro CT 
A Scanco micro CT system (µCT20, Scanco Medical AG, Bassersdorf, 
Switzerland) was used to obtain both trabecular (11 µm voxel size) and cortical 
parameters (13 µm voxel size). Right tibiae were separated and fixed in 10% neural 
buffered formalin for 48 hours, then stored in 70% ethanol. Trabecular bone parameters 
were obtained by analyzing 1.65mm (150 slices) trabecular bone immediately distal to 
the growth plate at the proximal end of the tibia. These parameters include total volume 
(TV), trabecular bone volume (BV), percent connectivity of trabecular struts, and 
trabecular volume fraction (BV/TV). Bone mineral density data were also obtained from 
the CT scans. A phantom (Scanco) with increasing density hydroxyapatite columns was 
scanned by microCT; the linear curve of hydroxyapatite content was used as the standard 
curve to obtain the mineral content of the bones. Bone density data were calibrated to 
milligrams of hydroxyapatite per cubic centimeter. 
Left femora were air-dried and scanned for cortical parameters. A 24 mm length 
of femoral diaphysis was analyzed with a total of 49 slices at 500 µm increments between 
slices (13 µm voxel size with 487 µm void space between slices). Cortical volume and 
polar moment of inertia (pMOI) data were obtained using IPL-Moment-of-Inertia 
software (Scanco). 
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4.2.4 Biomechanical testing 
Mechanical properties were determined from femoral diaphyses and necks. After 
the cortical bone was scanned, left femora were rehydrated in phosphate buffered saline 
(PBS) for 90 min prior to testing to mimic in vivo properties (Broz, Simske et al. 1993). 
Three-point bending tests were performed using an Instron 5582 (Merlin, Series IX 
software); femora were tested to failure with a 24 mm span length and 5mm/min 
deflection rate. The force-deflection curves were analyzed to determine the strengths and 
deflections at the elastic, maximum, and failure limits. Stiffness was calculated by 
dividing elastic strength by elastic deflection.  
Right femora were air-dried and sectioned at the middle of the third trochanter. 
The proximal portions were embedded vertically in noninfiltrating Epo-Kwick epoxy 
(Buehler, Lake Bluff, IL) from the mid-trochanter to 2 mm distal to the base of the 
femoral neck (Ross, Bateman et al. 2001). Disks were rehydrated in PBS for 90 minutes 
prior to testing and then placed firmly in the Instron 5582. Loads were applied on the 
heads of the femora with a rate of 5mm/min until failure (Figure 4.4). Strengths, 
deflections, and stiffness were analyzed as previously described.  
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Figure 4.4 Photograph of mechanical test on femoral neck 
4.2.5 Mineral content analysis 
Distal epiphyses, femoral diaphyses and femoral head were separated from the 
fractured left femur. Mineral content data were obtained separately from each of these 
parts. Dry mass (Dry-M) was measured after heating the bones for 24 h at 105 ºC. 
Mineral mass (Min-M) was measured after the bones had been ashed by baking for 
another 24h at 800 ºC. Organic mass (Org-M) was calculated as Dry-M minus Min-M. 
Percent mineralization (%Min) was calculated by the formula % Min = Min-M/Dry-M * 
100%. 
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4.2.6 Quantitative histomorphometry 
The distal portions of the right femora were placed in 10% neutral-buffered 
formalin for 48 hours, rinsed with distilled water, and stored in ethanol. Bones were then 
air-dried for 96 hours and embedded with noninfiltrating Epo-Kwick epoxy (Buehler). 
Disks were sectioned using a low-speed saw (Buehler, 12.7cm x 0.5mm diamond blade) 
at the mid-diaphysis. The distal sections were wheel-polished to a flat, smooth surface 
using 600-, 800- and 1200-grit carbide paper followed by polishing with a cloth 
impregnated with 6 µm diamond paste. This allowed micrographs (25X magnification) of 
the bone cross-sections under a far blue light (400nm wavelength). Calcein labels in bone 
fluoresce green, identifying bone formation sites during the period of the study. 
Quantitative histomorphometric analyses were performed using SigmaScan Pro software 
(SPSS, San Rafael, CA) on these photographs.  
Measurements of bone morphology included total bone area (T.B.Ar) enclosed by 
periosteal perimeter and endocortical area (Ec.Ar) (Parfitt, Drezner et al. 1987). Cortical 
area was calculated as T.B.Ar – Ec.Ar. At the periosteal surface, area between labels was 
measured as periosteal bone formation area (Ps.BFA); linear content of the labeled area 
was defined as active mineralizing perimeter (Ps.AMPm). Periosteal bone formation rates 
were calculated by dividing the 24 days between the two injected labels by periosteal 
bone formation area (Ps. BFR = Ps. BFA/24) and mineral apposition rate as Ps.MAR = 
Ps.BFR/Ps.AMPm. At the endosteal surface, endocortical bone resorption perimeter 
(Ec.Rs.Pm) was measured by quantifying the portion of the nonlabeled surface with 
rough border. Bone formation was not quantified on the endocortical surface because a 
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significant portion of the calcein labels was clearly eroded in many of the rats, making 
accurate measurements not possible. 
4.2.7 Vascular analysis 
At sacrifice, after removal of hind limbs, the entire arterial trunk from the aortic 
arch to the bifurcation of the iliac arteries was dissected manually from each rat. After 
being rinsed in saline, the abdominal aorta segment (1-1.5 cm length) was processed for 
calcium analysis. Tissues were lyophilized, weighed, and dry weight was recorded. Dry 
samples were placed in 1 ml 6 N HCl and completely hydrolyzed in a boiling water bath 
for 8 hours. Samples were evaporated under a continuous stream of nitrogen gas; residual 
material was dissolved in 1 ml 0.01 N HCl. Calcium content was determined with an 
atomic absorption spectrophotometer (Perkin-Elmer Model 3030, Perkin-Elmer, 
Norwalk, CT). Values are expressed as µg calcium/mg dry aorta (Analysis above was 
performed by Dan Simionescu and Dina Basalyga). 
4.2.8 Statistics 
Statistical comparisons were performed using repeated measures of analysis of 
variance (ANOVA) with SigmaStat software. One-way ANOVAs, with a Tukey test for 
follow-up comparisons, were used. A 95% level of significance (type I error) was used 
for each of these tests. The correlation between serum TRAP-5b levels and bone strength 
was obtained from Pearson Product Moment Correlation test with SigmaStat. Data are 
presented as mean + standard error (SE). 
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4.3 Results 
4.3.1 Serum markers 
Expected residue drug volume was observed in each osmotic pump, indicating the 
successful delivery. Serum bone turnover marker levels were greatly enhanced in the rats 
treated with high-dose RANKL. TRAP-5b levels increased steeply during the first week 
of the study, peaking on day 7 with a five-fold increase (p<0.001 HI vs. VEH).  TRAP-5b 
levels gradually declined after day 7 and eventually returned to baseline levels at sacrifice 
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Figure 4.5 TRAP-5b (bone resorption marker) levels in HI increased steeply during the first 
week of the study, peaking on day 7 with a five-fold increase, and gradually declined to baseline 
at sacrifice. Data are presented as the mean ± SE. *: p<0.001 vs. VEH. 
Similarly, serum osteocalcin levels for the HI group gradually increased and 
peaked on day 14 at 82% higher (p<0.001) than VEH, then decreased over the course of 
the following two weeks, ending at 40% higher than the VEH (p<0.05) at sacrifice 




























Figure 4.6 Serum osteocalcin (bone formation marker) levels in HI gradually increased and 
peaked at day 14 with an 82% higher than the VEH, then decreased and ending at 40% higher 
than VEH. Data are presented as the mean ± SE. *: p<0.001 vs. VEH. 
Serum levels of human RANKL were measured from samples taken at sacrifice.  
Human RANKL was detectable in all animals, including vehicle controls, consistent with 
modest cross-reactivity of the assay’s human polyclonal RANKL antisera with 
endogenous murine RANKL.  Human RANKL levels in the high dose group were 5-fold 
higher than levels found in VEH controls (Figure 4.7); consistent with the notion that 
drug delivery was maintained for the study duration. Neither dose of RANKL caused 



























Figure 4.7 huRANKL levels at sacrifice were five-fold higher in HI than in VEH. Data are 
presented as the mean ± SE. *: p<0.001 vs. VEH. 
4.3.2 MicroCT analysis 
The low dose of RANKL was generally associated with few skeletal changes that 
reached statistical significance.  However, analysis of trabecular bone at the proximal 
tibia revealed trends towards significant reductions in trabecular bone volume (-11%, p= 
0.126) and trabecular connectivity (-17%., p = 0.054) compared to VEH. For the HI 
group, RANKL treatment induced significant decreases in microCT-derived measures of 
cortical and trabecular bone mass. High-dose RANKL treatment resulted in 7.6% 
reduction in cortical bone volume (p<0.05, Figure 4.8) and 64% reduction in trabecular 
volume fraction (BV/TV, p<0.001, Figure 4.9) compared to VEH. No differences were 












































Figure 4.8 Cortical bone properties were obtained via MicroCT analysis from the femoral 
diaphyses. (A) Cortical volume reduced by 7.6% in the HI group (p<0.05 vs. VEH), no change 
was observed in the LOW. (B) No significance differences were observed in Polar Moment of 
Inertia (pMOI) at mid-femoral diaphyses. Data are presented as the mean ± SE. *: Significant 
different vs. VEH. 
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Trabecular connectivity density was affected by RANKL at a relatively higher 
degree: Rats treated with high dose RANKL decreased in Conn-Dens. by 86% (p<0.001, 
HI vs. VEH, Figure 4.9). Bone density values were calibrated to milligrams of 
hydroxyapatite per cubic centimeter. Rats in the HI group exhibited a 1.5% decrease in 
bone density compared to VEH (p=0.002, Figure 4.11).  
VEH LOW HI  















































Figure 4.10 Trabecular bone properties were obtained via MicroCT analysis from the proximal 
tibias. (A) Trabecular volume fraction (BV/TV) decreased by 64% in HI (p<0.001 vs. VEH), 
trend of decrease was observed in LOW (p= 0.126 vs. VEH). (B) Connectivity density (Conn-
Dens.) decreased by 86% (p<0.001) in HI, trend of decrease by 17% was observed in LOW 

























Figure 4.11 Bone mineral density data obtained from the trabecular bone at proximal tibia 
showed a 1.5% decrease in HI compared to VEH (p<0.05. Data are presented as the mean ± SE. 
*: Significantly different vs. VEH. 
4.3.3 Bone strength 
Low-dose RANKL did not result in any functional changes in bone strength for 
either the femoral diaphysis or neck. However, high-dose RANKL treatment caused 
significant reductions in parameters of bone strength. Rats treated with 175µg/kg/day 
RANKL exhibited parallel declines in mechanical properties for both femoral diaphyses 
and femoral necks (Figure 4.12). For the femoral diaphyses, elastic, maximum, fracture-
strength and elastic-stiffness of the rats in the HI group decreased by 18%, 21%, 22%, 
and 13% (p<0.05) compared to VEH, respectively. In the femoral necks, high-dose 
RANKL treatment decreased elastic and maximum strength by 20% and 17% (p<0.05) 
compared to VEH. In HI group rats, elastic stiffness and fracture strength exhibited 
trends of decrease by 18% (p=0.061) and 17% (p=0.11) compared to VEH, respectively 
































































Figure 4.12 In femur mechanical properties, no differences were observed in the rats treated with 
low-dose RANKL. However, High-dose RANKL infusion degraded femur mechanical properties 
in both diaphyses and necks with a similar manner (A-D). Decreased mechanical parameters were 
observed from elastic strength (A, 18%), maximum strength (B, 21%), fracture strength (C, 22%) 
and elastic stiffness (D, 13%, vs. VEH) at femoral diaphyses though three-point bending tests. 
Similarly, high-dose RANKL treatment decreased elastic, maximum strength by 20% (A) and 
17% (B, p<0.05) and fracture strength, elastic stiffness, by 17% (C, p=0.105) and 18% (D, 
p=0.061), respectively, at the femoral neck region compared to VEH. Data are presented as the 
mean ± SE. *: p<0.05 vs. VEH. 
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4.3.4 Bone compositional Analysis 
For the LOW group, no differences were observed for Dry-M, Min-M, Org-M, or 
%Min at any testing site compare to VEH. However, rats in the HI group exhibited a 
2.7% (p<0.05) lower whole-femur %Min compared to VEH, and site-specific effects in 
the changes of %Min were observed: Distal epiphyses and femoral heads exhibited 8.0% 
and 3.0% lower %Min, respectively (p<0.001 vs. VEH); changes in femoral diaphyses 
were not significant (Table 4.1).  
Table 4.1 Mineral content analysis data were collected separately from femoral diaphyses, distal 
epiphyses and femoral heads. No differences in dry mass (Dry-M), mineral mass (Min-M), 
organic mass (Org-M) or percent mineralization (%Min = Min-M/Dry-M) were observed in any 
site of the LOW group. However, rats in HI decreased 2.7% (p<0.05) whole femur %Min and 
exhibited site specific effects: Distal epiphyses and femoral heads exhibited 8.0% and 3.0% lower 
%Min (p<0.001 vs. VEH), while %Min in femoral diaphyses remained unchanged. Data are 
presented as the mean ± SE. a, b: p<0.05, a, c: p<0.001, #: p=0.055 vs. LOW. 
 
 
4.3.5 Quantitative Histomorphometry 
There were no morphometric, formation, or resorption-related changes in the 
cortical bone of LOW rats as identified by quantitative histomorphometry. For the HI 
group, analysis of the femur mid-diaphysis revealed the deleterious effects of RANKL on 
cortical bone structure (Table 4.2). High-dose RANKL significantly increased 




Dry-M (mg) 664 ± 13 676 ± 13 634 ± 12# 
Min-M (mg) 422 ± 9a,b 430 ± 9a 393 ± 9b  
Org-M (mg) 242 ± 5 247 ± 5 242 ± 4 
%Min Whole Femur 63.5 ± 0.3a 63.5 ± 0.4a 61.8 ± 0.4b 
%Min Diaphysis 68.1 ± 0.5 68.7 ± 0.3 67.9 ± 0.4 
%Min Distal Epiphysis 55.3 ± 0.4a 54.1 ± 0.6a 50.9 ± 0.6c 
%Min Head 65.6 ± 0.3a 65.2 ± 0.3a 63.6 ± 0.3c 
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endocortical bone resorption, as evidenced by a 50% increase in endocortical resorption 
perimeter (Ec.Rs.Pm) compared to VEH.  This resulted in the endocortical area (Ec.Ar) 
being significantly greater in the HI group than in the LOW group (p<0.05), though the 
difference versus VEH did not reach statistical difference. Periosteal bone formation rate 
(Ps.BFR) was accelerated by high-dose RANKL administration, with the HI group 
exhibiting a 35% higher periosteal bone formation rate than the LOW (p<0.05). 
Additionally, there were trends in periosteal active mineralizing perimeter (p=0.051) and 
mineral apposition rate (p=0.088) with high-dose RANKL: Both increased compared to 
LOW. 
Table 4.2 Quantitative histomorphometric data were obtained from cross-sections of femoral 
diaphyses. No differences were observed in LOW. For HI, endocortical resorption perimeter 
(Ec.Rs.Pm) increased by 50% (p<0.05 vs. VEH), leading to 20% greater endocortical area 
(Ec.Ar) compared to LOW (p<0.05). Periosteal bone formation rate (Ps.BFR) was accelerated by 
35% (p<0.05 vs. LOW) by high-dose RANKL administration. There were trends in periosteal 
active mineralizing perimeter (Ps.AMPm) and mineral apposition rate (Ps.MAR) being increased 
by high-dose RANKL compared to LOW. Bone formation was not quantified on the endocortical 
surface due to a significant portion of the calcein labels being eroded. Data are presented as the 
mean ± SE. a, b: p<0.05, #: P=0.066 vs. LOW; *: p = 0.051 vs. LOW; §: P=0.088 vs. LOW. 
 
RANKL treated Measurement VEH 
 LOW (35 µg/kg) HI (175 µg/kg) 
Ec.Ar. (mm2) 4.64 ± 0.13a,b 4.28 ± 0.18a 5.13 ± 0.22b 
Tt.B.Ar (mm2) 14.08 ± 0.16 13.76 ± 0.34 14.06 ± 0.25 
Ct. Ar (mm2) 9.44 ± 0.13 9.48 ± 0.21  8.93 ± 0.19# 
Ps.BFR (10-3 mm2/day) 10.8 ± 0.7a,b 9.5 ± 1.0a 12.8 ± 1.0b 
Ps.AMPm (mm) 12.21 ± 0.41 10.80 ± 0.66 12.51 ± 0.37* 
Ps.MAR (10-3 mm/day) 0.89 ± 0.04 0.86 ± 0.04 1.01 ± 0.06§ 
Ec.Rs.Pm (mm) 1.62 ± 0.12a 1.54 ± 0.15a 2.43 ± 0.25b 
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4.3.6 Vascular calcification 
Atomic absorption spectrophotometry was used to assess calcium content in 
abdominal aortas, and neither dose of RANKL caused any significant changes in calcium 
content (Table 4.3).  
Table 4.3 No differences were observed in the calcium content levels of the abdominal aorta. 
Data are presented as the mean ± SE. 
 
Measurement VEH LOW (35 µg/kg RANKL) HI (175 µg/kg RANKL) 




0.22 ± 0.03 0.23 ± 0.02 
 
4.4 Discussion 
Numerous studies have identified the critical physiological and pathological roles 
of the RANK/RANKL/OPG pathway in a variety of skeletal diseases.  The RANKL:OPG 
ratio may be central to the regulation of bone remodeling in postmenopausal 
osteoporosis, rheumatoid arthritis, bone metastases, and other skeletal disease states. It 
has been shown that postmenopausal women express higher levels of RANKL in bone 
marrow preosteoblasts and T and B lymphocytes than premenopausal women or 
postmenopausal women receiving estrogen replacement therapy (Eghbali-Fatourechi, 
Khosla et al. 2003).  Interestingly, serum RANKL levels were not different among these 
patient populations, which is consistent with the possibility that serum RANKL levels do 
not reflect the levels found within bone.  RANKL levels in serum are typically very low 
and frequently below the detection limits of current assays (Abrahamsen, Hjelmborg et 
al. 2005).  These limitations have made it difficult to identify the effects of RANKL on 
aspects of bone mass, density, microarchitecture, geometry and quality. 
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We attempted to elucidate these relationships by creating a new animal model of 
high-turnover bone disease that is driven by the continuous infusion of soluble 
recombinant RANKL.  In rats treated with high-dose RANKL, microCT scans revealed 
an overall loss of bone volume in both trabecular and cortical sites, as well as the a loss 
of trabecular connectivity, which are commonly seen in skeletal diseases (Coleman 1997; 
Hofbauer and Schoppet 2004). Although there were no significant differences in bone 
microarchitecture in the LOW group, there were trends in both trabecular volume fraction 
and trabecular connectivity with no changes in other parameters. It is interesting to note 
that, for this group, there were no corresponding changes in serum markers for bone 
resorption or formation at any time point during the study. Furthermore, serum levels of 
human RANKL were not significantly greater than the background levels found in 
vehicle-treated mice.  These results suggest that RANKL may be capable of causing 
deleterious changes in bone mass in the absence of marked changes in circulating levels 
of RANKL itself, or biochemical markers of bone turnover.  This possibility is consistent 
with clinical observational studies, wherein serum RANKL concentrations failed to 
correlate with bone disease despite observed increases in the levels of RANKL within 
bone (Stilgren, Hegedus et al. 2003; Stilgren, Rettmer et al. 2004).  
Bone turnover had been identified as one of the major factors determining bone 
quality and skeletal fragility (Turner 2002; Heaney 2003). OPG-deficient mice (OPG-/-) 
produce a high bone-turnover osteoporotic phenotype with significant decreases in bone 
mineral density and strength (Bucay, Sarosi et al. 1998). The analysis of sequential serum 
markers for the current rat study demonstrated that bone turnover responded to increased 
circulating RANKL levels with a coupled increase in both bone formation and resorption.  
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RANKL injections led to a maximal 5-fold increase in serum TRAP-5b, which exceeded 
the maximal increase in serum osteocalcin (~2-fold).  These changes, in addition to the 
clear loss of bone mass, density and strength, indicate that the catabolic actions of 
RANKL are not effectively countered by the observed increases in bone formation.  
These effects were observed in growing gonad-intact rats, which would otherwise exhibit 
a positive bone remodeling balance.  These observations indicate that RANKL-mediated 
bone remodeling might result in bone loss independent of age, sex hormone levels, age, 
or baseline levels of bone turnover or density.   
The accelerated bone resorption resulted in hypercalcemia as described in the 
pilot study, which is a common metabolic complication of malignant diseases associated 
with morbidity (Coleman 1997). Due to the coupling effect between osteoclasts and 
osteoblasts, bone formation markers increased accordingly with a delay relative to the 
increase in resorption, peaking on Day 14, and remained at high levels through the end of 
the study. This sequential stimulation of bone resorption and formation correlates with 
the activation sequence in normal skeleton remodeling cycle. Most osteolytic metastases 
demonstrate similar changes in bone resorption and formation, with the dominant lesion 
being lytic and destructive but coupled by elevated formation (Mundy 2002).  
In this study, we observed that serum TRAP-5b levels returned to baseline after 
28 days of RANKL infusion.  To test whether this decline was related to premature 
exhaustion of the osmotic pumps, we measured human RANKL levels from serum 
collected at sacrifice.  Significant levels of human RANKL were observed at the end of 
the study in the high-dose group, which indicates that drug delivery was maintained 
throughout the study.  However, RANKL concentrations were relatively low at the end of 
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the study (~250 pg/ml in the high-dose group) and it is possible that immune responses 
against human RANKL led to lower drug exposure during the latter phase of the infusion 
period.  Nonetheless, the high-dose infusion regimen was shown to cause significant bone 
loss over a 4 week period, which establishes this as a useful model of high-turnover bone 
disease for future studies.  It is also possible that the gradual recovery of serum TRAP-5b 
levels during the latter phase of RANKL infusion was related to a homeostatic response 
that attempts to minimize the severity of bone loss.  The osteoporotic phenotype of OPG-
deficient mice shows that even a lifetime of unopposed RANKL activity does not lead to 
complete resorption of the skeleton (Bucay, Sarosi et al. 1998).  It is therefore likely that 
compensatory mechanisms eventually defend the skeleton against the extremes of bone 
loss, perhaps via a feedback increase in bone formation.   
A direct consequence of this high bone turnover model was degraded bone 
quality, which includes poor material properties and inferior bone architecture. Bone 
mineralization status can be indicated as material properties. When calibrated with 
hydroxyapatite content, bone density on trabecular bone showed a 1.5 % decrease in the 
HI compared to VEH as revealed by MicroCT . The changes in mineralization status 
were also indicated by the decrease of percent mineralization at bone cortical and 
trabecular regions. Both techniques demonstrate that high-dose RANKL infusion resulted 
in poor mineralization, which is probably a consequence of the increased turnover.  
Quantitative histomorphometric analysis of the femoral mid-diaphyses revealed 
the effects of RANKL on cortical bone. The decreased femoral cortical volume, as 
identified by microCT, was caused by stimulation of endocortical bone resorption, which 
resulted in thinning of the cortex. This observation correlates with a previous study 
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demonstrating that OPG reverses osteoporosis by inhibiting activation of endosteal 
osteoclasts (Min, Morony et al. 2000). Correlated to the high osteocalcin levels observed 
in serum, periosteal bone formation rate increased in the HI group. However, this positive 
effect on bone strength was counteracted by greater endocortical resorption, as confirmed 
by the three-point bending test.  
Strength of the femoral neck is a composite of both cortical and trabecular bone 
properties. Extrapolating the cortical and trabecular changes observed at other sites, it is 
clear that the combination of reduced trabecular architecture, poor trabecular 
mineralization, and inferior cortical structure resulting from high-dose RANKL infusion 
compromised strength at the femoral neck. These observations in gonad-intact rats are 
consistent with data showing that the ratio of RANKL:OPG is elevated in 
postmenopausal women with prevalent hip fractures (Abdallah, Stilgren et al. 2005).  The 
ability of RANKL inhibitor to improve femoral neck BMD and geometry in 
postmenopausal women appears to confirm that RANKL plays a role in bone turnover at 
this clinically important skeletal site (Beck, Miller et al. 2006). 
Vascular calcification has been indicated to be closely related to 
RANK/RANKL/OPG pathway; OPG knock-out mice develop arterial calcification of the 
renal arteries and aorta (Min, Morony et al. 2000). However, analysis of the calcium 
content from abdominal aortas indicated that continuous RANKL administration did not 
cause vascular calcification.  It is possible that systemic exposure to RANKL does not 
induce or exacerbate vascular disease.  Alternatively, RANKL-related changes in the 
vasculature might require a longer infusion period or the presence of additional vascular 
insults or challenges.  This study utilized healthy rats, and it remains possible that 
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RANKL could have deleterious effects on the vasculature in animals that are more 
susceptible to vascular disease.   
4.5 Conclusions 
In summary, high-dose RANKL infusion resulted in systemic bone loss and 
decline in bone quality and structural integrity that were comparable to the skeletal 
complications caused by diseases such as osteoporosis. Thus, therapies targeting 
inhibition of RANKL may be a viable approach in treating skeletal complications of 
these bone diseases (Body, Facon et al. 2006; McClung, Lewiecki et al. 2006). 
Continuous administration of RANKL resulted in low bone mass and reduced bone 
strength without obvious complications or toxicities. Modification of RANKL 
administration (local to a joint rather than systemic) could possibly mimic the peri-
articular bone loss and/or focal bone erosions that are associated with rheumatoid 
arthritis. The model presented here (and variations thereof) could have utility as a model 
of high-turnover bone disease, and for characterizing the potential role of the 
RANKL/RANK/OPG pathway for multiple skeletal diseases.  
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CHARACTERIZATION OF M-CSF AS AN ANABOLIC AGENT FOR BONE 
BIOMECHANICS 
5.1 Introduction 
Macrophage colony-stimulating factor (M-CSF, also named CSF-1) was defined 
originally by its ability to stimulate the growth and development of macrophage colonies 
from bone marrow precursors (Stanley, Guilbert et al. 1983). Subsequent studies showed 
that M-CSF is a haematopoietic growth factor that stimulates the proliferation, 
differentiation, and survival of cells from the mononuclear phagocytes lineage, including 
macrophages and osteoclasts (Hume, Pavli et al. 1988; Rettenmier and Sherr 1989; 
Hattersley, Owens et al. 1991). M-CSF is produced primarily by connective tissue cells, 
including stromal cells and osteoblasts. Through alternative mRNA splicing of a unique 
gene, these cells synthesize three mature isoforms of M-CSF, including a membrane-
bound glycoprotein, an extracellular matrix-anchored proteoglycan, and a soluble 
glycoprotein that is rapidly secreted into the circulation (Stanley, Berg et al. 1994). These 
M-CSF isoforms act on target cells through a specific cell-surface tyrosine kinase 
receptor (CSF-1R) that is encoded by the c-fms proto-oncogene (Pixley and Stanley 
2004).  
In bone, M-CSF acts as a key regulator of osteoclastogenesis both in vitro and in 
vivo. Previous studies showed that M-CSF is necessary for both proliferation and 
differentiation of osteoclast progenitors as well as for their survival (Fuller, Owens et al. 
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1993; Tanaka, Takahashi et al. 1993). In a coculture system of mouse osteoblasts and 
spleen cells, osteoclast formation induced by 1,25(OH)2 Vitamin D3 was inhibited when 
the coculture system was incubated with either anti-M-CSF or anti-M-CSF receptor 
antibodies during the proliferation or differentiation phase (Tanaka, Takahashi et al. 
1993). The role of M-CSF in osteoclastogenesis in vivo has been confirmed using M-
CSF-deficient osteopetrotic (op/op) mouse model. Transgenic mice with specific knock-
out of the M-CSF gene developed profound osteopetrotic phenotypes with little or no 
osteoclast activity (Wiktor-Jedrzejczak, Bartocci et al. 1990; Yoshida, Hayashi et al. 
1990). Subsequent studies demonstrated that systemic administration of recombinant 
human M-CSF to op/op mice increased the number of osteoclasts and led to partial or 
complete resolution of the osteopetrotic defect (Kodama, Yamasaki et al. 1991; Abboud, 
Woodruff et al. 2002).  
It is clear that M-CSF stimulates osteoclastogenesis by promoting early entry of 
progenitors into the osteoclast lineage. However, there is no evidence that M-CSF 
stimulates the later stages of osteoclastogenesis, such as fusion and activation, or 
subsequent bone resorption (Biskobing, Fan et al. 1995; Udagawa, Takahashi et al. 
1999). In fact, several studies have reported that high concentrations of M-CSF can 
suppress osteoclast formation and activation in vitro (Hattersley, Dorey et al. 1988; 
Fuller, Owens et al. 1993; Perkins and Kling 1995). For example, Perkins et al. showed 
that exogenous M-CSF caused a dose-dependent 98% decrease in tartrate-resistant acid 
phosphatase (TRAP)-positive multinucleated cells in a coculture system of ST-2 stromal 
cells and murine bone marrow cells (Perkins and Kling 1995). In studies using isolated 
mature rat osteoclasts, Hattersley and Fuller demonstrated that M-CSF inhibited bone 
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resorption by reducing the proportion of osteoclasts that were resorbing bone (Hattersley, 
Dorey et al. 1988; Fuller, Owens et al. 1993). Furthermore, addition of M-CSF has been 
shown to down-regulate the expression of its receptor c-fms on macrophages and isolated 
osteoclasts (Panterne, Zhou et al. 1993; Amano, Hofstetter et al. 1995; Fan, Biskobing et 
al. 1997). 
These findings suggest a complex action of M-CSF in bone physiology: It 
stimulates the proliferation and differentiation of osteoclast progenitors but exhibits 
antiresorptive effects by inhibiting formation of mature osteoclasts and their functional 
activities. Recently, studies showed that mice over-expressing M-CSF or receiving daily 
M-CSF injections increased cortical bone formation and improved cortical bone material 
and biomechanical properties (Hermann 2000; Abboud, Ghosh-Choudhury et al. 2003). 
 Osteoblasts play an integral role in regulating osteoclastogenesis through both 
cell-cell interactions and release of cytokines (Takahashi, Akatsu et al. 1988; Teitelbaum 
2000). These bone formation responses, possibly induced by the coupling phenomena 
between osteoclasts and osteoblasts (Nishino, Amizuka et al. 2001), demonstrate the 
potential of M-CSF as an anabolic agent for osteolytic bone diseases, such as 
osteoporosis. However, many important anabolic indicators of the skeleton, such as bone 
turnover rates and trabecular bone formation and geometry, have not been examined. In 
the present study, we explored a series of functional changes of the skeleton in response 
to different doses of M-CSF, with the aim of further characterizing its potential as an 
anabolic agent. 
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5.2 Materials and Methods 
5.2.1 Study design 
Prior to the main study, two pilot studies were performed using lower doses of M-
CSF. In study I, seven-week-old C57BL/6J male mice (Jackson Laboratory, Bar Harbor, 
ME) received two different doses of M-CSF (0.01 mg/kg/day, 0.1 mg/kg/day) via daily 
injections for 3 weeks. In study II, mice of the same strain and age received a 4-week 
administration of two higher doses of M-CSF (0.5 mg/kg/day, 1 mg/kg/day) via both 
daily injections and continuous administrations using osmotic pumps. At sacrifice, hind 
limbs were removed and analyzed; no differences in bone volume, geometry, 
mineralization, or strength were observed. Therefore, a higher dose of M-CSF 
(5mg/kg/day) was selected in this study to examine its in vivo effects on bone 
biomechanics. 
In the main study, twenty-four male C57BL/6J mice aged 7 weeks were assigned 
to one of two groups, VEH (placebo control, phosphate buffered saline, n=12) or M-CSF 
(5 mg/kg/day, n=12). The protein used in this project was donated by Chiron 
(Emeryville, CA); it was an unglycosylated 49-kDa homodimer (a truncated form of 
native M-CSF) that was expressed in Escherichia coli and stored as a lyophilized powder. 
All mice received daily subcutaneous injections (0.2 ml per injection) for 21 days. Body 
weights were monitored every three days, and drug concentrations were adjusted 
accordingly. Calcein (20 mg/kg) was injected (i.p.) as a fluorescent label at Day 2 to 
monitor new bone growth. On Day 21, animals were anesthetized with isoflurane and 
euthanized by exsanguination followed by cervical dislocation. Both hind limbs were 
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Figure 5.1 Flowchart illustrating the study design of the M-CSF study 
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All procedures performed throughout the experiment conformed to the guidelines of 
Clemson University’s Institutional Animal Care and Use Committee (Figure 5.1). 
5.2.2 Serum bone-turnover markers 
Serum was obtained at sacrifice, and markers for bone formation and resorption 
were measured. Serum osteocalcin and TRAP-5b levels were measured as markers of 
bone formation and bone resorption by ELISA (SBA Science/IDS Inc.), respectively.  
5.2.3 Micro CT 
Left tibiae and femurs were fixed in 10% neural buffered formalin for 2 days, 
rinsed with distilled water, and stored in 70% ethanol. Cortical and trabecular parameters 
were obtained from the microcomputed tomography analysis (µCT20, Scanco Medical 
AG, Bassersdorf, Switzerland) with a voxel size of 9 µm in all three spatial dimensions 
(Ruegsegger, Koller et al. 1996; Dufresne 1998). Left femoral diaphyses were scanned, 
and a total of 75 slices, with 100µm increments between slices, were analyzed for cortical 
bone parameters. To determine bone volume and polar moment of inertia, contours were 
traced at the periosteal surface and calculated by Scanco IPL-Moment software.  
Trabecular bone parameters were obtained from the microCT scans of 0.9 mm 
trabecular bone sections at the proximal end of tibiae, immediately distal to the growth 
plate. These parameters included trabecular bone volume (BV), total volume (TV), 
connectivity density (Conn. Dens.) of trabecular struts, trabecular number (Tb.N), and 
trabecular separation (Tb.Sp). BV was normalized with TV to obtain trabecular volume 
fraction (BV/TV). Trabecular number was calculated by taking the inverse of the mean 
distance between the middle axes of the trabeculae; trabecular separation was calculated 
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by measuring 3D distances directly in the trabecular network and taking the mean over all 
voxels. A phantom (Scanco) with increasing density hydroxyapatite columns was 
scanned by microCT; the linear curve of hydroxyapatite content was used as the standard 
curve to obtain the mineral content of the bones. Bone density data were obtained and 
calibrated to milligrams of hydroxyapatite per cubic centimeter. 
5.2.4 Biomechanical testing 
Mechanical properties of left femora were tested following microCT analysis. All 
bones were removed from ethanol, rinsed with distilled water, and rehydrated in 
phosphate-buffered saline (PBS) for 1.5 hours prior to mechanical testing. Three-point 
bending tests were performed using an Instron 5582 (Merlin, Series IX software). Femora 
were tested to failure with an 8 mm span length and deflection rate of 5mm/min. Force 
(N) and deflection (mm) were measured at the elastic limit (Pe, δe), maximum force, and 
failure for all mechanically tested bones. Stiffness (S) was calculated from Pe/δe.  
5.2.5 Mineral content analysis 
Mineral content analysis was performed on the fractured femur. Prior to analysis, 
epiphyses at both proximal and distal ends were separated. Mineral-content data were 
obtained separately from epiphyses and diaphysis. Dry mass (Dry-M) was measured after 
heating the bones for 24 h at 105ºC. Mineral mass (Min-M) was measured after the bones 
had been ashed by baking for another 24 h at 800ºC. Percent mineralization (%Min) was 
calculated by the formula % Min = Min-M/Dry-M * 100%.  
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5.2.6 Quantitative histomorphometry 
Left femora were air-dried and embedded with noninfiltrating Epo-Kwick epoxy 
(Buehler, Lake Bluff, IL). The formed disks were sectioned with a low-speed saw 
(Buehler, 12.7cm x 0.5mm diamond blade) at the mid-diaphysis of the femur. The 
sections were wheel-polished to a flat, smooth surface using 600-, 800-, and 1200-grit 
carbide paper followed by polishing with a cloth impregnated with 6 µm diamond paste. 
This allowed micrographs at 50X magnification to be taken of the bone cross-sections 
under a far blue light (400 nm). Green calcein labels were visualized, indicating the bone 
formation sites during the period of the study. Quantitative histomorphometric analysis 
was performed using these photographs and SigmaScan Pro software (SPSS, San Rafael, 
CA).  
Measurements of bone morphology (Parfitt, Drezner et al. 1987) included total 
bone area (Tt.B.Ar) and endocortical area (Ec.Ar), cortical area was calculated as Tt.B.Ar 
– Ec.Ar. Bone formation area (BFA) was obtained by measuring the area between the 
labels and the cortical perimeter, and linear content of the labeled perimeter was defined 
as active mineralizing perimeter (aMPm). Bone-formation rates were calculated as BFR = 
BFA/19 days, and mineral apposition rate was calculated as MAR = BFR/aMPm 
separately in the periosteal (Ps.BFR, Ps.MAR) and endocortical (Ec.BFR, Ps.MAR) 
areas.  
5.2.7 Statistics 
Statistical comparisons were performed using unpaired t-tests with SigmaStat 
software. A 95% level of significance (type I error) was used for each of these tests. Data 
are presented as mean + standard error (SE). 
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5.3 Results 
5.3.1 Body and spleen mass 
Animal mass in both groups increased during the 21-day study. Mice in the VEH 
group increased body mass from 19.5 grams at Day 0 to 21.5 grams at Day 21, while 
those treated with M-CSF experienced a 55% higher net body mass gain than the VEH 
mice (p=0.001); average body mass increased from 19.3 grams at Day 0 to 22.4 grams at 
sacrifice. Significant differences in the net increases of body mass between VEH and M-
CSF groups were observed from Day 3 (p<0.001) and continued to the end of the study 
(Figure 5.2). At sacrifice, spleens were removed and weighed; mice treated with M-CSF 

































Figure 5.2 Animal mass in both groups increased during the 21-day study. Mice in the VEH 
group increased body mass from 19.5 grams at Day 0 to 21.5 grams at Day 21. Significant 
difference in net increases of body mass between VEH and M-CSF groups were observed from 
Day 3 (p<0.001) and remained to the end of the study. At sacrifice, mice treated with M-CSF 
gained an average of 3.1 gram body mass, increased from 19.3 grams at Day 0 to 22.4 grams, 
which was 55% higher than those in the VEH mice (p=0.001). Data are presented as the mean ± 
SE. * = significantly different from VEH. 
5.3.2 Bone turnover 
Daily administration of M-CSF stimulated general bone turnover in mice, as 
evidenced by significantly increased bone formation and resorption rates. Serum 
osteocalcin levels (marker of bone formation) in M-CSF group increased 44% compared 
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to VEH (p<0.001). Meanwhile, the bone specific resorption marker, serum TRAP-5b 


















































Figure 5.3 M-CSF increased both bone formation and resorption rates. (A) Serum osteocalcin 
exhibited 44% higher in the M-CSF group (167ng/ml) than VEH (116ng/ml, p<0.001). (B) Serum 
TRAP-5b levels in the M-CSF group (13.2 U/L) increased by 57% compared to VEH (8.4U/L, 
p<0.001). Data are presented as the mean ± SE. * = significantly different from VEH. 
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5.3.3 Cortical Strength 
Mechanical properties of the cortical bone were obtained from femur diaphyses. 
Between the groups of M-CSF and VEH, significant differences were not observed in any 
of the elastic, maximum, fracture strength or energy (Table 5.1). 
Table 5.1 Three point bending tests were performed on femur diaphyses to obtain mechanical 
properties data of the cortical bone. Significant differences were not observed in any of the 
elastic, maximum, fracture strength or stiffness. Data are presented as the mean ± SE.  
 
Measurements VEH M-CSF 
Stiffness (N/mm) 39.2 ± 2.1 41.5 ± 4.5 
Elastic force (N) 9.05 ± 0.31 8.89 ± 0.21 
Maximum force (N) 11.8 ± 0.4 11.7 ± 0.3 
Fracture force (N) 6.17 ± 0.30 6.62 ± 0.38 
 
5.3.4 Bone mineral content 
Bone mineral data were obtained separately from femoral diaphyses and 
epiphyses. No differences in dry mass (Dry-M), mineral mass (Min-M), organic mass 
(Org-M) were observed in the M-CSF group compared to VEH. Data in percent 
mineralization in sites of diaphyses, epiphyses or whole femur between groups were 






Table 5.2 Mineral content analysis data were collected separately from femoral 
diaphyses and epiphyses. In the M-CSF group, no differences in dry mass (Dry-M), 
mineral mass (Min-M), organic mass (Org-M) were observed compared to VEH. 
Differences in percent mineralization (%Min = Min-M/Dry-M) in sites of diaphyses, 
epiphyses or whole femur were also not observed (vs. VEH). Data are presented as the 
mean ± SE.  
 
 
5.3.5 Bone volumes indicated by MicroCT 
M-CSF caused differential effects in mouse cortical and trabecular bone. Cortical 
bone volumes were measured and calculated in a 7.4 mm span of the femur diaphysis. M-
CSF caused a trend of decrease in cortical volume by 2.9% compared to VEH (p=0.095, 
Figure 5.4A), though data did not reach statistical difference. Similar trends were 
observed in the average polar moment of inertia (pMOI) data; M-CSF treatment resulted 
in a trend of decrease by 5.8% in pMOI value of the femur diaphysis (p=0.074 vs. VEH, 
Figure 5.4B).  
Measurement VEH M-CSF 
Dry-M (mg) 33.0 ± 0.6 32.3 ± 0.9 
Min-M (mg) 20.0 ± 0.4 19.7 ± 0.5 
Org-M (mg) 13.0 ± 0.2 12.7 ± 0.4 
%Min Whole Femur 60.6 ± 0.1 60.8 ± 0.2 
%Min Diaphysis 62.6 ± 0.3 62.6 ± 0.3 












































Figure 5.4 No significant differences were observed in cortical bone parameters between M-CSF 
and VEH groups. However, trends of decreased cortical volume (A) by 2.9% (p=0.095) and mean 
polar moment of inertia (pMOI) of femur diaphyses (B) by 5.8% were observed in the M-CSF 
group compared to VEH. Data are presented as the mean ± SE. * = significantly different from 
VEH. 
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Trabecular parameters were measured from a 0.9 mm thick section of trabecular 
bone in proximal tibia. In contrast, average trabecular volume fraction (BV/TV) 
increased by 35% in the mice treated with M-CSF (p<0.001 vs. VEH, Figure 5.5A). M-
CSF significantly increased trabecular connectivity by 79% (p<0.001, Figure 5.5B) 









































Figure 5.5 M-CSF stimulated trabecular bone formation. (A) Average trabecular volume fraction 
(BV/TV) increased by 35% (p<0.001 vs. VEH) in mice treated with M-CSF. (B) M-CSF 
significantly increased trabecular connectivity by 79% (p<0.001) compared to the VEH group. 




Figure 5.6 Trabecular parameters were measured with microCT from a 0.9 mm thick trabecular 
bone section at proximal tibia. 3-D trabecular pictures showed the mouse treated with M-CSF has 
a thicker and denser trabecular bone than that in VEH. Both pictures were obtained from mice 
with median bone volume of individual groups.  
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Significant differences were also observed in other trabecular parameters: M-CSF 
increased trabecular number by 17.7% (p<0.001, Figure 5.7A), and lower trabecular 
spacing by 17.8% (p<0.001, Figure 5.7B) compared to VEH. Bone density values were 
calibrated to milligrams of hydroxyapatite per cubic centimeter. Mice in the M-CSF 


















































Figure 5.7 M-CSF also affected other trabecular bone parameter, such as increased trabecular 
number (A) by 17.7% (p<0.001), and lower trabecular separation (B) by 17.8% (p<0.001 vs. 






























Figure 5.8 The newly formed trabecular bone induced by M-CSF administration exhibited a 
3.5% lower bone density than those in VEH (p=0.007). Data are presented as the mean ± SE. * 
= significantly different from VEH. 
5.3.6 Quantitative histomorphometry 
As indicated by quantitative histomorphometry, M-CSF administration did not 
cause significant changes in cortical geometry (Table 5.3). However, trends of increase in 
periosteal mineral apposition rate (Ps.MAR, p=0.12) and total mineral apposition rate 






Table 5.3 Quantitative histomorphometry measurements were taken from the UV microscope 
photographs of the femur mid-diaphysis cross-sections. Ec = endocortical, Ps = periosteal, Tt = 
total, Ar = area, B = bone, BFR = bone formation rate, AMPm = active mineralizing perimeter, 
MAR = mineral apposition rate. Data are presented as mean ± SE. 
 
Measurement VEH M-CSF 
Ec.Ar. (mm2) 0.85 ± 0.03 0.82 ± 0.03 
Ct. Ar (mm2) 0.81 ± 0.02 0.80 ± 0.02 
Tt.B.Ar (mm2) 1.66 ± 0.03 1.63 ± 0.01 
Ec.BFR (10-3 mm2/day) 2.11 ± 0.36 2.03 ± 0.21 
Ps.BFR (10-3 mm2/day) 5.60 ± 0.34 6.44 ± 0.54 
Tt.BFR (10-3 mm2/day) 5.42 ± 0.36 5.42 ± 0.36 
Ec.AMPm (mm) 1.87 ± 0.17 1.80 ± 0.13 
Ps.AMPm (mm) 3.39 ± 0.29 3.37 ± 0.30 
Tt. AMPm (mm) 5.26 ± 0.31 5.17 ± 0.31 
Ec.MAR (10-3 mm/day) 1.09 ± 0.12 1.12 ± 0.07 
Ps.MAR (10-3 mm/day) 1.72 ± 0.11 1.96 ± 0.10 p=0.12 




Bone remodeling, a lifetime process that includes bones being continuously 
broken down (bone resorption) and reformed (bone formation), allows the maintenance 
of bone mass and quality. Activities of osteoblasts and osteoclasts are tightly linked and 
balanced under normal conditions, a phenomenon often referred to as coupling (Howard, 
Bottemiller et al. 1981; Martin 1993). In this study, we observed an increase of 
osteoclastogenesis, as evidenced by the 57% increase in serum TRAP-5b levels. 
Meanwhile, bone formation activities (serum osteocalcin) also increased, indicating M-
 149
CSF indirectly stimulated bone formation through coupling of osteoblasts and 
osteoclasts. The mechanism of the coupling phenomena, though not fully understood, is 
generally considered to be the result of direct communication between osteoclasts and 
osteoblasts by cell-cell interaction and by cytokines released to the bone 
microenvironment during bone resorption (Howard, Bottemiller et al. 1981; Centrella, 
McCarthy et al. 1991; Rodan 1991; Martin 1993). Previous studies have indicated that 
these coupling factors might include insulin-like growth fact-1 (IGF-1), transforming 
growth factor-β (TGF-β), and bone morphogenetic factor (BMP) (Centrella, McCarthy et 
al. 1991; Rodan 1991; Martin 1993).  
Although both bone turnover rates increased, the most evident changes in bone 
came from the markedly increased trabecular volume, indicating that M-CSF dissociated 
bone remodeling and functioned as an anabolic agent. Mice treated with high doses of M-
CSF showed increased trabecular volume (35%), connectivity density (79%), and 
trabecular number (17.7%) and reduced separation (-17.8%). The newly formed 
trabecular bone was less mineralized due to the high bone turnover rates, as revealed by 
the microCT data. Anabolic effects of M-CSF also came from the increased body mass 
observed in this study; mice treated with M-CSF gained significantly higher body weight 
from Day 3 and remained throughout the whole course of this study.  
Anabolic effects of M-CSF were not reflected in cortical bone. Data obtained in 
this study showed that M-CSF induced a nonsignificant trend of decreasing cortical 
volume and polar moment of inertia. However, these probably catabolic effects on 
cortical bone did not cause significant changes in bone strength. In fact, the presence of 
both anabolism and catabolism is common in most bone anabolic agents (Lacey, Timms 
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et al. 1998; Poole and Reeve 2005). Other cortical bone parameters, including geometry 
and mineralization, remained unchanged. Interestingly, these observations on cortical 
bone are opposite compared to previous findings of increased cortical thickness or 
improved mineral and mechanical properties in studies with either transgenic models or 
lower-dose M-CSF administrations (Hermann 2000; Abboud, Ghosh-Choudhury et al. 
2003).  
The clear increases in trabecular bone parameters and the trend of decrease in 
cortical bone volume indicated that M-CSF exhibits both anabolic and catabolic effects 
with site-specific differences. Similar results are known in anabolic agents for 
osteoporosis, such as  PTH (Poole and Reeve 2005). Anabolic effects of intermittent PTH 
injections were observed primarily in trabecular bone through increasing trabecular bone 
volume, connectivity density and trabecular number and decreasing separation (Jiang, 
Zhao et al. 2003). Along with these strong anabolic actions on trabecular bone, PTH 
stimulates endocortical bone remodeling and increases cortical porosity, a catabolic effect 
that has led to concern that the increases in trabecular bone parameters may be obtained 
at the expense of cortical bone (Horwitz, Stewart et al. 2000; Neer, Arnaud et al. 2001; 
Rubin, Cosman et al. 2002). Such site-specific anabolic and catabolic changes in bones 
are similar to those induced by M-CSF in this study. 
However, PTH acts anabolically by directly stimulating bone formation through 
promoting differentiation of committed osteoblast precursors and inhibiting apoptosis of 
osteoblasts (Dobnig and Turner 1995; Jilka, Weinstein et al. 1999) In contrast, M-CSF 
targets osteoclast lineage and stimulates the proliferation and early differentiation of 
osteoclast progenitors but not mature osteoclasts (Tanaka, Takahashi et al. 1993), thus 
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indirectly promoting osteoblast formation via coupling. These two seemingly radically 
different mechanisms may not be fully independent. Recent studies have indicated that 
the resorptive action of PTH might be necessary for its anabolic effect. In a study using 
ovariectomized rats treated with PTH, bone formation was partially inhibited with a 
combined treatment of antiresorptive therapies (Wronski, Yen et al. 1993). Transgenic 
mice with c-fos gene knock-out exhibit osteopetrotic symptoms due to defects on 
osteoclast development and fail to show an anabolic response to PTH (Demiralp, Chen et 
al. 2002).  
In vivo studies targeting the effects of M-CSF on the skeleton system are sparse; 
however, complicated action of M-CSF has been seen. In vitro studies demonstrated 
divergent effects of M-CSF on osteoclast formation and bone resorption in varying 
concentrations (Perkins and Kling 1995). The importance of protein concentrations was 
also reflected in the pilot studies for this project. In these in vivo studies, we examined a 
series of lower doses of M-CSF (0.01mg, 0.1mg., 0.5mg, and 1mg per kilogram body 
mass per day) given to mice of the same strain and age as the current 5mg/kg/day M-CSF 
study, and neither anabolic nor catabolic effects on the skeleton were observed in the 
mice receiving lower doses. This might indicate that M-CSF causes dose-dependent bone 
functional changes. In addition, administration routes and periods might also cause 
different bone reactions. An in vivo study using transgenic mice that overexpressed 
soluble M-CSF showed no changes in bone parameters at 5 weeks but had increased 
cortical bone thickness at 14 weeks (Abboud, Ghosh-Choudhury et al. 2003). One 
possible explanation for this observation might be the variety of the M-CSF-receptor 
expression. Earlier studies by other groups showed that M-CSF receptors could be 
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expressed at variable levels under different populations of monocyte cells and local 
cytokine environments (Kreipe, Radzun et al. 1988; Gusella, Ayroldi et al. 1990). As a 
stimulator of circulating monocytes and macrophages, M-CSF can influence the local 
environments of its receptor. In addition, M-CSF itself can down-regulate its receptor 
expression in macrophages and isolated osteoclasts (Amano, Hofstetter et al. 1995). 
5.5 Conclusions 
In summary, this study demonstrates the anabolic actions of M-CSF on trabecular 
bone formation. These anabolic effects, probably through coupling between osteoclasts 
and osteoblasts, suggest the potential of M-CSF as an anabolic agent to stimulate new 
bone formation and improve bone strength. In vitro studies have shown that M-CSF in 
higher concentrations exhibits unique antiresorptive effects on bone resorption; however, 
these antiresorptive effects were not observed in this in vivo study. Future studies 
examining changes in skeleton exposed to different dosages, administration routes, and 
periods or effects in larger and skeletally mature animals like rats will be necessary to 
elucidate the mechanism and utilize its anabolic potential. In addition, since soluble M-
CSF exhibits a relatively short clearance time in the circulation (Bauer, Gibbons et al. 
1994), further modifications on molecular structures or drug delivery methods aiming to 
improve the pharmacokinetics and pharmacodynamics of this protein would be valuable 
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CONCLUSIONS AND RECOMMENDATIONS 
This dissertation has examined two key cytokines for osteoclastogenesis 
regulation (RANKL and M-CSF) and their opposing effects on bone biomechanics. This 
concluding chapter will highlight the novel findings from the three major animal studies 
and their pilots studies detailed in the previous three chapters, and propose suggestions on 
future direction based on these findings. 
6.1 Conclusions 
Studies in this project have characterized the in vivo catabolic effects of RANKL 
as the late stage regulator and final effector for osteoclastogenesis on bone biomechanics; 
examined and proposed RANKL-induced skeletal deterioration model as a novel animal 
model for osteolytic skeletal diseases; and characterized the in vivo anabolic effects of M-
CSF as the early stage regulator for osteoclastogenesis and its potential of acting as an 
innovative anabolic therapy for osteoporosis. During the above explorations, a series of 
novel findings has been concluded in which the details are described as below.  
1. Daily injections of soluble RANKL directly activated osteoclastogenesis and 
stimulated general bone turnover rates, resulting in hypercalcemia.  
2. Soluble recombinant RANKL caused severe catabolic effects on both cortical and 
trabecular bone in a short period of time. These effects include: increases in bone 
resorption, reduces in both cortical and trabecular bone volume, decreases in both 
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cortical and trabecular bone mineralization, impairments in cortical bone 
architecture and reduces in cortical bone strength.  
3. Excessive RANKL levels led to a coupling-related increase in bone formation at 
the periosteal surface of cortical bone. However, these increased bone formations 
were insufficient to counteract deleterious effects on other areas.  
4. Therapies targeting inhibition of RANKL might be a viable approach in treating 
skeletal complications of high-turnover bone diseases like osteoporosis. 
5. The RANKL injection study on mice has some limitations, including the lack of 
an obvious dose-response for many of the endpoints. We believe that a lower dose 
range would have provided a clearer dose response for the majority of parameters. 
Dose-dependent weight loss and hypercalcemia indicated that RANKL 
administration at 2 mg/kg was an excessive dose that resulted in toxicity.  
6. In the RANKL infusion study, we have used soluble RANKL to develop a new 
animal model for high-turnover bone diseases without obvious complications or 
toxicities. This novel animal model recapitulates many of the deleterious skeletal 
changes associated with postmenopausal osteoporosis in which details are 








Table 6.1 Comparisons of bone functional changes between postmenopausal women and 
RANKL induced bone loss model 
 
Postmenopausal women RANKL induced bone loss model 
• Bone mineral density decreases • Cortical and trabecular bone volume lost 
• Trabecular bone mineralization reduced 
• Integrity of trabecular bone geometry 
reduces 
• Trabecular bone volume decreased 
• Trabecular connectivity density reduced 
• Medullary cavity increases • Endocortical bone resorption rate 
increased 
• Endocortical bone area increased 
• Periosteal diameter (bone size) increases • Periosteal bone formation rate increased 
• Fracture risk increases • Bone strength at femur mid-diaphysis and 
femoral neck reduced 
 
7. Bone turnover rates responded to increased circulating RANKL levels with a 
coupled increase in both bone formation and resorption. Due to the coupling 
phenomena, bone formation markers increased accordingly with a delay relative 
to the increase in resorption, and correlates with the activation sequence in normal 
skeleton remodeling cycle.  
8. The lower dosage of RANKL infusion induced trends of decrease in trabecular 
bone parameters without corresponding changes in serum bone turnover markers 
and circulating RANKL levels. These results suggested that RANKL may be 
capable of causing deleterious effects in bone volume and structure in the absence 
of changes in circulating levels of RANKL itself, or biochemical markers of bone 
turnover.  
9. RANKL administrations induced a homeostatic response that attempts to 
minimize the severity of bone loss. The osteoporotic phenotype of OPG-deficient 
mice shows that even a lifetime of unopposed RANKL activity does not lead to 
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complete resorption of the skeleton (Bucay, Sarosi et al. 1998). It is therefore 
likely that compensatory mechanisms eventually defend the skeleton against the 
extremes of bone loss, perhaps via a feedback increase in bone formation.  
10. Analysis of the calcium content from abdominal aortas indicated that continuous 
RANKL administration did not cause vascular calcification. It is possible that 
systemic exposure to RANKL does not induce or exacerbate vascular disease. 
Alternatively, RANKL-related changes in the vasculature might require a longer 
infusion period or the presence of additional vascular insults or challenges. This 
study utilized healthy rats, and it remains possible that RANKL could have 
deleterious effects on the vasculature in animals that are more susceptible to 
vascular diseases.  
11. High dose M-CSF administration resulted in marked increases in trabecular bone 
formation and general bone turnover rates. These novel findings indicated that M-
CSF dissociated bone remodeling which favored bone resorption, and have 
demonstrated the potential of M-CSF as a potent anabolic agent for bone strength.  
12. Systemic anabolic effects of M-CSF were reflected by the increases in body mass. 
Mice treated with M-CSF gained significantly higher body weight from Day 3 
and remained throughout whole course of the study. 
13. In this study, we observed increases in both osteoclastogenesis and bone 
formation activities. M-CSF receptors exist on surfaces of osteoclasts and their 
progenitors but not osteoblasts. These findings indicated that M-CSF indirectly 
stimulated bone formation through coupling of osteoblasts and osteoclasts.  
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14. M-CSF induced trends of decrease in cortical bone parameters without changes in 
bone strength. These observations on cortical bone were contradictory to previous 
findings of increased cortical thickness in transgenic models over expressing M-
CSF (Abboud, Ghosh-Choudhury et al. 2003). 
15. The evident increases in trabecular bone parameters and trend of decrease in 
cortical bone volume indicated that M-CSF exhibits both anabolic and catabolic 
effects with site-specific differences. These region specific observations are 
similar to those induce by PTH. 
16. Pilot studies of the M-CSF study indicated a dose dependent effect of M-CSF on 
bone biomechanics. Analysis of the data also indicated that there is a dose 
threshold for M-CSF to induce bone functional changes. 
17. In summary, activations of later and early stages of osteoclastogenesis, through in 
vivo administration of RANKL and M-CSF, induced general opposing changes on 
bone volume, structure, mineralization and strength. RANKL directly stimulated 
bone resorption and degraded bone biomechanical properties. The bone loss 
animal model induced by RANKL exhibited a series of skeletal complications 
similar to those observed in high-turnover osteolytic skeletal diseases such as 
osteoporosis. On the other hand, administrations of M-CSF markedly stimulated 
trabecular bone formation and had less of an influence on cortical bone. These 
changes demonstrated the potential of M-CSF as an anabolic agent for 
osteoporosis. 
18. Findings in this project, such as the creation of a RANKL induced bone loss 
model and characterization of M-CSF as an innovative anabolic agent for bone 
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biomechanics, could provide a useful tool and information for further explorations 
on the battles with human skeletal diseases.  
6.2 Recommendations 
6.2.1 RANKL Induced Bone Loss Model 
Studies in this project have created an animal bone loss model induced by 
RANKL administrations. To make this novel model a practical tool for future studies on 
the field of skeletal diseases, further studies on optimizing this model are recommended: 
1. In our studies, we administrated RANKL at high dosages via daily injections on 
mice and long-term continuous administrations with lower dosages on rats, to 
ensure the fully catabolic consequences. The amount of RANKL administered to 
animals appeared excessive. Future studies examining the minimal dosage and 
administration periods of RANKL on mice or rats will be helpful to lower the 
toxicity, expense, studies period and increase the practicality of the model. It is 
recommended to further examine the duration of the bone destructive status in this 
model which is the body’s natural recovery response after RANKL induced bone 
loss.  
2. It will be of further interest to examine the expression levels of up-stream 
cytokines, such as PTHrP, IL-1, IL-6, M-CSF and TGF-β in this RANKL induced 
bone loss model. These cytokine expression levels will provide valuable 
information on the mechanisms of cytokine interaction, indications of skeletal 
homeostasis from the protein level and predict the skeletal responses.  
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3. Future studies are recommended to examine the therapeutic agents for skeletal 
diseases, such as OPG, PTH, and bisphosphonates with this model. These studies 
may provide further information on therapeutic efficacy and disease mechanisms 
that were not captured by other models.  
6.2.2 Development of M-CSF as a Novel Anabolic Agent for Osteoporosis 
In this project, M-CSF showed good potential as an innovative anabolic agent for 
bone biomechanics. However, due to the limited in vivo data available in the literature, 
the detailed mechanism and functional effects of M-CSF on the skeletal system require 
further examination. Future recommended studies are:  
1. Lower efficacious doses and optimum administration periods and routes of M-
CSF, with the capability to induce anabolic response without causing toxicity or 
immune responses, remain to be characterized.  
2. Mechanisms of coupling, such as signal transductions through osteoclasts-
osteoblasts direction interaction, and changes in cytokine levels in bone 
microenvironment after coupling is triggered by M-CSF, are also recommended 
for further examination.  
3. Examinations of M-CSF efficacy on disease models, such as OVX and RANKL 
induced bone loss model as described in this study, will provide further 
information on this anabolic agent in addition to those observed in healthy mice 
of this project. 
4. Soluble M-CSF exhibited a relatively short clearance time in the circulation 
(Bauer, Gibbons et al. 1994). Modifications on molecular structures or drug 
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delivery methods, aiming to improve the pharmacokinetic and pharmacodynamics 
of this protein remain to be developed.  
5. The antiresorptive potential of M-CSF indicated by in vitro studies was not 
observed in current in vivo studies. These antiresorptive effects, if observed in 
future studies in vivo, will greatly enhance the potential of M-CSF being a 
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Appendix A: Examination of M-CSF Protein Degradation  
 
 The M-CSF protein used in this project was donated by Chiron, manufactured 15 
years ago. To examine potential protein degradation, SDS-PAGE and Western Blot 
analyses were performed. 
Materials and Methods 
 The protein sample (3.9 mg/ml) was serial diluted (10%, 1%, and 0.2%) then 
mixed with an equal volume of loading buffer. For the SDS-PAGE gels (Piece), 10µl of 
each concentration was loaded. Thus, 19500ng, 1950ng, 195ng and 39ng of M-CSF were 
loaded per lane. The molecular weight marker, Kaleidascope (Biomad) was loaded (5 µl). 
A voltage of 120V for 60 minutes was used. The SDS-PAGE gel was then stained with 
Coomassie Blue to visualize the protein. Western blot were used to confirm that the 
protein bands observed on the SDS-PAGE gels were M-CSF and its degraded isoforms. 
The primary antibody to M-CSF was a rabbit monoclonal from Genetex. A goat anti-
rabbit IgG antibody was used as the secondary antibody. All procedures for Western Blot 
followed the instructions from Bio-Rad. 
Results 
 
The serially diluted samples of M-CSF resulted in multiple bands on the gels. 
Based on comparison of the loaded samples, approximately 2-8% of the protein was 
degraded. The antibodies detected the lower molecular weight bands on the western blots, 
indicating that both the primary band and the degraded bands were M-CSF (Figure A.1).  
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Figure A.1 SDS-PAGE gel and Western blot membrane analysis of the recombinant M-CSF used 
in these studies confirmed the degradation. The lanes labeled 100%, 10%, 1% and 0.2% 
contained 19500ng, 1950ng, 195ng and 39ng of M-CSF, respectively. The observed degradation 
is between 2 to 8% of the total protein in the sample. MW: Molecular weight.
 
 
Appendix B: Low Dose Administration of Macrophage-Colony Stimulating Factor 
in Mice 
 
Part of the M-CSF pilot study I data submitted to Rocky Mountain Bioengineering 
Symposium as a conference article in 2004: “Low dose administration of macrophage 
colony-stimulating factor in mice.” Biomed Sci Instrum. 2004;40:93-8. 
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Macrophage-Colony Stimulating Factor (M-CSF) is critical for osteoclast differentiation 
and development.  It has been previously observed that M-CSF administration and over-
expression in mice causes an increase in cortical bone formation.  We hypothesize that 
M-CSF increases osteoblast activity indirectly via coupling of these two bone cells.  In 
this study, we examined the impact on bone properties of relatively low doses of M-CSF 
in mice.  Four groups of seven-week old C57BL/6J mice were used: (1) baseline (age) 
controls, (2) placebo controls, (3) 10µg/kg/day M-CSF, (4) 100µg/kg/day M-CSF.  
Injections were administered daily for the 21-day study.  Three bone labels of calcein and 
tetracycline were alternately administrated (days 0, 9 and 18) to allow quantification of 
new bone formation.  MicroCT scans (15 micron resolution) were performed on the 
proximal end of the right tibiae (1.0 mm section of trabecular bone) and left femur mid-
diaphysis (0.25 mm cortical section).  Dry mass, mineral content and percent mineral 
composition were obtained from the left tibiae.  Functional changes were not detected in 
the bone of these mice receiving low doses of M-CSF.  In particular, as previous studies 
have reported in mice receiving high doses of M-CSF or transgenic mice overexpressing 
bone specific M-CSF, changes to cortical bone did not occur with the lower doses.  This 
may indicate that high doses of M-CSF and/or longer periods of administration may be 




Macrophage-Colony Stimulating Factor (M-CSF or CSF-1) is a haematopoietic growth 
factor that is produced mainly by connective tissue cells, including osteoblasts (Felix, 
Halasy-Nagy et al. 1996).  M-CSF is essential for the cells from the mononuclear 
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phagocytes lineage, from which osteoclasts are derived (Kodama, Nose et al. 1991).  It is 
known that M-CSF facilitates monocyte survival, monocyte-to-macrophage conversion, 
and macrophage proliferation (Corboz, Cecchini et al. 1992; Fixe and Praloran 1997).  In 
vitro, it has been shown to promote osteoclastogenesis in bone (Corboz, Cecchini et al. 
1992; Sundquist, Jackson et al. 1995; Sarma and Flanagan 1996).  The ability of M-CSF 
to stimulate osteoclast in vivo has been confirmed by using the M-CSF-deficient 
osteopetrotic (op/op) mouse model (Kodama, Yamasaki et al. 1991; Sundquist, Jackson 
et al. 1995; Abboud, Woodruff et al. 2002).  Repeated injections of M-CSF increased the 
number of osteoclast, which lead to partial or complete correction of the osteopetrotic 
defect.  A dose-dependent relationship was observed during these treatments.  These 
studies demonstrate the ability of M-CSF to increase bone resorption in mice deficient in 
osteoclasts.   
 
However, recent studies on transgenic mice targeted expression of M-CSF showed 
increased cortical thickness and bone mineral density (Abboud, Ghosh-Choudhury et al. 
2003).  This osteoblast specific expression of soluble M-CSF greatly increased levels of 
M-CSF in the bone, resulting in increased bone formation rates at the endocortical 
surface.  Our group has observed similar results with the administration of M-CSF 
improving material and mechanical properties of cortical bone (Hermann 2000).  The 
increase in strength was mediated by a greater percent mineral composition, rather than 
an accelerated bone formation.  An increase in percent mineral composition is observed 
with the administration of anti-resorptive therapies (Bateman, Lacey et al. 1999; 
Bateman, Dunstan et al. 2000).   
 
These findings highlight the complex and important role of M-CSF in bone physiology, 
and demonstrated its potential as an unconventional therapy for osteoporosis.  Less clear 
evidence suggests that M-CSF actually inhibits mature osteoclast activity, potentially 
acting as an agent that promotes bone formation via coupling by promoting immature 
osteoclasts, but limiting the amount of bone resorption by mature osteoclasts.  This 
unique role in osteoclast development and survival may have a positive effect on both 
osteoblast’s and osteoclast’s increasing bone mass rather than inhibiting bone formation 
as current anti-resorptive therapies do.  To explore this hypothesis and to determine the 
optimum M-CSF dose for increasing cortical strength, we are examining two different 
doses of M-CSF (100 µg/kg/day and 100µg/kg/day).  These doses are 10% and 1% of the 
high dose previously examined by our group (Hermann 2000), and more similar to the 
dose of teriparatide (parathyroid hormone amino acids 1-34) that produces an anabolic 




In this study, 75 C57BL/6J (Jackson Labs, Bar Harbor, Maine, USA) mice seven-weeks 
in age were randomly assigned to four groups: (1) baseline (age) controls, (2) placebo 
controls, (3) 10µg/kg/day M-CSF, and (4) 100µg/kg/day M-CSF.  The baseline control 
group was sacrificed at the beginning of the study, the placebo, M-CSF (10µg/kg) and M-
CSF (100µg/kg) groups were administered saline, 10µg/kg M-CSF and 100µg/kg M-CSF 
through this 21-day study (i.p.).  The initial weights of all mice ranged from 18-22 gram, 
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the weights were monitored daily.  During this experiment, Calcein (s.c., 20 mg/kg, at 
days 0 and 18) and Tetracycline (s.c., 20 mg/kg, at day 9) were administered to all mice 
to allow the quantification of bone formation rates.  Clemson University animal care and 
use committee approved the animal protocol for this study.   
 
At the end of the study, all the mice were sacrificed via exsanguinations and followed by 
cervical dislocation.  Afterwards, the femora and tibiae were removed and cleaned off all 
non-osseous tissue.  The right femora and tibiae were fixed with 10% neutral buffered 
formalin for 48 hours and then stored in 70% ethanol.  The right femora was air dried and 
embedded in Epo-Quick epoxy (Buehler, Lake Bluff, IL), then sectioned at mid-diaphysis 
using a low speed saw (Buehler, 300µm diamond blade).  Photographs of the bone were 
taken at 50X under three different filters (FITC, Fs05, DAPI) to view the bone labels.  
Quantitative histomorphometric analysis will be performed on these cross-sections.   
 
The proximal end of the right tibiae was scanned with MicroCT (SCANCO Medical, 
µCT20, Zurich, Switzerland); trabecular bone approximately 1.0 mm beneath the growth 
plate was analysis.  The left femora were dried for 48 hours and a MicroCT scan was 
performed on the mid-diaphysis.  A 0.25 mm thick section of cortical bone was analyzed 
(15 micron resolution, 9 microns per slice, 28 slices); total volume and bone volume were 
obtained for all groups (Figure 1).  Mineral content of the left tibiae was analyzed, dry 
mass (Dry-M, 105C for 24 hours) and mineral content (Ash-M, 800C for 24 hours) were 
obtained on the proximal end and the diaphysis.  A one-way-ANOVA statistical 
comparison was used on all these tests, with a Tukey follow-up.  Data are reported as 




The mice weights increased normally during this 3-week study, the difference between 
placebo and M-CSF treated groups was not significant.  After examining the trabecular 
volume, trabecular number, trabecular thickness, trabecular spacing and the ratio of bone 
volume by total volume of the tibiae proximal end, changes between placebo, 10µg/kg 
M-CSF and 100µg/kg M-CSF groups were not significant, the bone volume/total volume 
increased with age compared to baseline group.  No significant changes were observed of 
the dry mass and ash mass of the tibiae proximal end and diaphysis.  MicroCT scan of the 
femora mid-diaphyseal cortical bone showed a normal increase of total volume and bone 
volume with age, but significant changes between placebo and M-CSF treated groups 






Figure 1.  MicroCT scan of cortical bone from the femur mid-diaphysis, 0.25 mm thick.  
ScanCo Medical, MicroCT 20 Scanner (15 micron resolution, 9 microns per slice, 28 
slices).   
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Figure 2.  MicroCT scan of Total/Bone Volume (mm2) of cortical bone in the femur, 






Previous studies with op/op mice showed increased osteoclasts and macrophages, thus 
proving that M-CSF is a potent growth and differentiation factor for cells of the 
mononuclear phagocyte lineage.  Discrepancies between the recoveries of osteoclasts and 
macrophages with respect to locations and dose responsiveness on the op/op mice was 
reported (Sundquist, Jackson et al. 1995), these suggest different regional sensitivities of 
these cells and their precursors to M-CSF for survival and differentiation.  For this study, 
low-dose M-CSF administration had no significant on cortical bone, as observed in other 
studies (Hermann 2000; Abboud, Ghosh-Choudhury et al. 2003).  It is important to note 
that M-CSF administration may have an anabolic effect on cortical bone, but not 
trabecular.  This difference was observed for mice over-expressing M-CSF (but not 
examined for our previous study administering M-CSF daily) (Hermann 2000; Abboud, 
Ghosh-Choudhury et al. 2003).  But it has been reported in previous study that increased 
cortical thickness and bone mineral density were showed with high level of M-CSF 
expression and long period of time [7], this may indicate that higher doses and longer 
period of administration time may be necessary to induce noticeable effects in cortical 







Daily administration of 10µg/kg and 100µg/kg M-CSF in mice produces no functional 
changes in cortical bone properties.  It is hypothesized that high doses (effectively 
flooding M-CSF receptors), and potentially longer period of administration, is needed to 
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